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Breast cancer screening program 
Worldwide breast cancer (BC) is the most common cancer and the leading cause 
of cancer death in women both in the developed and developing world.1 In 2008 
1.38 million women were diagnosed with BC, which is 23 per cent of all cancers, 
and 458.000 die from this disease annually.1 In the Netherlands one in eight 
women will get BC during her life.2,3  
BC screening with mammography has been introduced to detect BC before it is 
clinically apparent, thereby obtaining earlier detection with the potential to reduce 
BC mortality.4 The first mammography screening trial was performed in New York 
in the 1960s. Subsequently several trials were performed in the 1970s and 1980s 
in Sweden, the United Kingdom, and Canada.4,5 In the Netherlands, the first 
experimental BC screening was introduced in 1974. A nationwide screening 
program was initiated in 1988, with full coverage in 1997.5,6 Women in the age 
between 50 and 75 years receive an invitation for a BC screening mammogram 
every two years, which comes down to approximately one million women 
annually.5 The attendance rate of the BC screening program is around 80 per cent, 
with a recall rate up to 2 per cent and a false-positive rate of 66 per cent after 
recall.5,6,7 In comparison, in the United States the recall rate is 11 per cent after a 
first screening mammogram and 7 per cent after a subsequent screening 
mammogram and in the United Kingdom these percentages are 7 per cent and 4 
per cent respectively.8  
 
In the Western World the BC incidence is still increasing, but over decades the BC 
mortality has considerably decreased.1 One is inclined to think that this reduction of 
BC mortality is the result of earlier detection by the BC screening program. 
However, recent studies suggested that this decline in BC mortality is 
accomplished by the improvements of adjuvant BC treatment9,10,11, and that 
screening has little detectable impact on BC mortality.12,13 A recent Cochrane 
review revealed limited evidence for the idea that BC screening reduces BC 
mortality. The decrease in BC mortality of 15 per cent corresponds with an 
absolute risk reduction of 0.05 per cent.4 In addition, the number of mastectomy is 
20 per cent higher in women who are attending the BC screening program.4 
Whether the enhanced BC survival has been achieved by earlier detection through 
screening, better BC awareness, or by improved treatments is important to 
consider, because of the substantial disadvantages of the BC screening program, 
such as overdiagnosis, overtreatment, and a false-positive screening 
mammogram.4,14 Screening causes 30 per cent overdiagnosis and overtreatment, 
1
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and therefore, the harms of unnecessary treatment could outdo any potential 
benefit of the BC screening.4 The risk for a false-positive screening mammogram is 
estimated to be 49 per cent after ten mammograms in the United States and up to 
21 per cent in Norway.15,16 Women with a false-positive screening mammogram 
report ongoing anxiety with impaired quality of life (QoL) during and after the 
diagnostic work-up.4,17-20   
Thus, the disadvantages of the BC screening program are substantial and 
moreover, recent data has suggested that screening has little detectable impact on 
BC mortality.4,12,13 Therefore, we questioned whether the advantages still justify the 
disadvantages of the BC screening program. To contribute to this ongoing 
discussion, we believe it is important to determine the impact of an abnormal 
screening mammogram (ASM) on women’s psychological distress (state anxiety, 
depressive symptoms) and QoL.  
 
Breast cancer and distress and quality of life 
Up to 50 per cent of women diagnosed with BC experience higher levels of anxiety 
and distress during the diagnostic process.21-24 In women with BC, the prevalence 
of depression and depressive symptoms vary from 1.5 to 46 per cent.25 Before 
being diagnosed with BC, 28 per cent of women experience high anxiety in 
combination with depressive symptoms.26 This fact was found to be a major 
predictor for QoL 12 and 24 months after BC surgery.26 Women with benign breast 
disease (BBD) go through similar emotions.21-24 Previous studies have revealed a 
negative impact of the personality characteristic trait anxiety, which describes 
anxiety proneness27, on momentary anxiety, depressive symptoms, and QoL in 
both women with BC and BBD.22,24,28-30 Moreover, trait anxiety determined the 
impaired QoL in women with breast disease, regardless of the diagnosis being BC 
or BBD.31  
 
Aim and design of the study 
 
Thus, women report increased levels of anxiety, distress, depressive symptoms 
and impairment in QoL when undergoing the diagnostic work-up for BC (after an 
ASM), irrespective of being diagnosed with BC or BBD. We believe that a tailor-
made follow-up protocol would be useful to prevent the adverse psychological 
consequences in women (with high trait anxiety) during and after the diagnostic 
process for (malignant) breast disease. Before implementing such a protocol, we 
need to establish a number of things. Firstly, more insight should be gained about 
the extent of the psychological consequences of BC screening for women 
eventually diagnosed with BBD. Secondly, the adverse psychological effects could 
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be a reason for an increase in health care utilization during and after the diagnostic 
process for BC and BBD, especially in women with high trait anxiety. However, 
limited research concerning health care utilization in women with BC or BBD is 
performed. It is important to determine the patterns and predictors of health care 
utilization in women with breast disease, since it will be possible with this 
knowledge to anticipate to their needs and eventually adjust the current follow-up 
protocol guidelines. Thirdly, it is important to know whether the chronically anxious 
women are always more anxious, experience more depressive symptoms, and 
have an impaired QoL when confronted with a medical problem or whether this 
depends on the severity of diagnosis they are facing. 
 
Women who were referred to the outpatient breast clinic with a palpable lump in 
the breast or an ASM, were asked to participate in this study. The aim of the first 
part of this thesis was to examine the impact of being recalled for further diagnostic 
procedures after an ASM on women’s psychological distress (state anxiety, 
depressive symptoms) and QoL. Women diagnosed with BC or BBD after an ASM 
were compared. Furthermore, women were compared with regard to the timing of 
the screening mammogram (first versus repeat), and women with BBD referred 
after an ASM or referred with a palpable lump in the breast were compared. These 
two comparisons have not been performed before. To our knowledge, this is the 
first study analysing the influence of the personality characteristic trait anxiety on 
the psychological consequences in women with a false-positive screening 
mammogram. In addition, in our study the questionnaires were completed before 
the diagnostic procedures were performed, thus before the diagnosis BC or BBD 
was known. This renders a true baseline measurement.  
Thus far, only a few studies have examined the impact of an ASM on QoL. 
However, the majority of studies analysing “QoL” in women with BC or BBD 
measured health status, often referred to as health-related QoL. This is not 
equivalent to QoL and, therefore, not considered interchangeable. Health status 
measures the impact of disease on functioning whereas QoL also reflects to what 
extent a patient is bothered by these limitations in daily life.31 Therefore, in our 
study we measured QoL with the WHOQOL questionnaire which askes about 
satisfaction and not merely functioning.   
 
The second part of this thesis focuses on the impact of the personality 
characteristic trait anxiety on health care utilization, psychological distress (state 
anxiety, depressive symptoms) and QoL in women with breast disease. Firstly, we 
analysed health care utilization and its predictors in women with BC or BBD. So 
far, this is the first study examining the impact of the personality characteristic trait 
1
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anxiety on health care utilization. Secondly, we hypothesized that the severity of 
diagnosis, i.e. being confronted with a possible malignant breast disease, will also 
be an important predictor for psychological distress, in addition to the personality 
characteristic trait anxiety. Therefore, we compared women with BC or BBD with 
women with gallstone disease awaiting a laparoscopic cholecystectomy. To our 
knowledge, this comparison has not been performed before. The group of women 
with gallstone disease was chosen because it was previously found that trait 
anxiety had a negative impact on QoL and persisting symptoms in this group.32,33   
 
Questionnaires 
The questionnaires assessed personality (STAI-Trait, NEO-FFI), state anxiety 
(STAI-State), depressive symptoms (CES-D), fatigue (FAS) and QoL (WHOQOL-
100 and WHOQOL-Bref). Questionnaires were completed at baseline, and one, 
three, six and twelve months after the definitive diagnosis or surgery.  
The personality trait neuroticism was measured by the neuroticism part (12-items) 
of the Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI).34,35 
Neuroticism weighs emotional instability against emotional stability. The reliability 
and validity of this questionnaire are good.34 
The State and Trait Anxiety Inventory (STAI) was used to assess state anxiety and 
the personality characteristic trait anxiety. State anxiety is a momentary emotional 
condition characterized by subjective feelings of apprehension and tension, and 
heightened autonomic nervous system activity. Trait anxiety concerns differences 
in individuals in the disposition to respond to stressful situations, such as a 
possible diagnosis of BC, with varying amounts of stress.27,36 The original and 
short versions of the STAI-Trait and STAI-State were used. The psychometric 
properties of both versions are well established and considered good.27,36-39 
Depressive symptoms were measured with the Center for Epidemiological Studies-
Depression Scale (CES-D). The CES-D includes six components: depressed 
mood, feelings of guilt and worthlessness and hopelessness, psychomotor 
retardation, loss of appetite and sleep disturbance. However, no component scores 
can be calculated, only a total score may be used. It measures both the presence 
and the degree of depressive symptoms.40 The psychometric properties are 
good.40,41  
Fatigue was scored using the 10-items Fatigue Assessment Scale (FAS).42 It is a 
questionnaire that measures perceived fatigue and exhaustion. The reliability and 
validity of the FAS appear to be good in women with breast problems43 and the 
general population.42,44  
The World Health Organization Quality of Life assessment instrument (WHOQOL-
100) is a generic, cross-culturally multidimensional questionnaire.45,46 It consists of 
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100 items assessing 24 facets of QoL within six domains (Physical health, 
Psychological health, Level of independence, Social relationships, Environment 
and Spirituality) and a general evaluative facet (Overall QoL and General health). 
The reliability and validity of this questionnaire are good for women with breast 
disease.47 In addition, the WHOQOL-Bref has also been used, which is the short 
version of the WHOQOL-100 questionnaire.48 The WHOQOL-Bref consists of 
questions assessing QoL within four domains (Physical health, Psychological 
health, Social relationships and Environment) and a general evaluative facet 
(Overall QoL and general health). The psychometric properties of the WHOQOL-
Bref are considered good (WHOQOL) also in women with benign breast disease.49   
 
Outline of this thesis 
 
Chapter two describes the effect of an ASM on QoL and state anxiety until one 
year after diagnosis. Women with a false-positive screening mammogram were 
compared with women diagnosed with BC after an ASM. In addition, the effect of 
trait anxiety on QoL and state anxiety was examined.  
In chapter three the adverse psychological consequences after an ASM in women 
with BBD were analysed. We were especially interested in the timing of the 
screening mammogram, i.e. first or repeat screening mammogram, and the effect 
on psychological distress (anxiety, depressive symptoms) and QoL. The impact of 
trait anxiety on these psychological factors was also analysed.   
In chapter four we examined whether the previously found adverse psychological 
effects are found in all women diagnosed with BBD or in particular in women 
referred after an ASM. Women with a false-positive screening mammogram were 
compared with women with a palpable lump in the breast and diagnosed with BBD. 
The influence of trait anxiety on the psychological distress was studied.   
In chapter five we evaluated the health care utilization and its predictors in women 
with BC or BBD during the first year following the diagnosis. Women diagnosed 
with BC were compared with women with BBD, and the influence of trait anxiety on 
health care utilization was studied. 
In chapter six we analysed whether high state anxiety and depressive symptoms 
previously found in women with BC or BBD were determined solely by the 
personality characteristic trait anxiety or whether it was caused by personality in 
combination with the severity of diagnosis, a possible life-threatening disease (i.e. 
BC). To examine this, we compared women with breast disease before diagnosis 
is known (BC or BBD) with women with a non life-threatening disease, i.e. 
gallstone disease awaiting an elective laparoscopic cholecystectomy.    
1
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BC). To examine this, we compared women with breast disease before diagnosis 
is known (BC or BBD) with women with a non life-threatening disease, i.e. 
gallstone disease awaiting an elective laparoscopic cholecystectomy.    
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In chapter seven we compared women with BC or BBD with women with gallstone 
disease awaiting a laparoscopic cholecystectomy to determine the impact of trait 
anxiety and/or the severity of diagnosis on QoL.   
Finally, chapter eight contains the summary and discussion on the study results, 
and the clinical implications with the future perspectives.  
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Screening for breast cancer reduces breast-cancer related mortality. Advantages 
of screening are explained clearly, but its disadvantages are underrepresented in 
consent folders.  
 
Methods  
In September 2002 a prospective, longitudinal study started concerning quality of 
life (QoL) in women with breast disease. Between September 2002 and January 
2007, 385 women with an abnormal screening mammogram were included. Of 
these, 152 women were diagnosed with breast cancer (BC group) and 233 had a 
false-positive result (FP group). Questionnaires concerning anxiety (State and Trait 
Anxiety Inventory) and QoL (World Health Organization Quality of Life assessment 




The BC group was significantly older (60 versus 57 years, p<0.001); significantly 
more histological biopsies were needed in the FP group (p<0.001). Almost 60 per 
cent of the FP group revisited the outpatient clinic in the first year. Trait anxiety had 
a profound influence on QoL. Women in the FP group with a high score on trait 
anxiety had lowest QoL on all measurement (p<0.001). They also reported more 
feelings of anxiety compared with women in the FP group with a lower trait anxiety 
score, and women in the BC group with a low trait anxiety score (p<0.001). 
 
Conclusions  
Women with a false-positive diagnosis of screen-detected breast cancer had a low 
QoL and feelings of anxiety, especially when they scored high on trait anxiety. This 
effect lasted for at least one year. 
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Cancer screening is intuitively appealing, and common sense dictates that early 
detection is good and without risks.1,2 Most screening programs for breast cancer 
(BC) have proven successful in decreasing BC related mortality.3,4 In the 
Netherlands the invitation to undergo mammography sent to women every two 
years claims survival advantages, but does not mention the potential uncertainties 
and pitfalls in a clear way.5 The Dutch screening program has a 1 per cent recall 
rate for assessment. It is known that common psychological reactions during 
detection, diagnosis, and treatment of cancer include anxiety and depression.6,7 
Being recalled for further investigation after an abnormal screening mammogram is 
a stressful experience for many women.8 Short-term effects include depressive 
symptoms and anxiety, especially when an additional biopsy is necessary.9  
It is not only the woman who decides to participate in BC screening who has the 
anxiety and psychological burden, her family and social support are included.  
In this prospective, longitudinal study the possible risks and negative side-effects 
of false-positive results in BC screening were examined. The study analysed the 
effects of (possibly) unnecessary diagnostic procedures and treatment, and the 
impact of a false-positive result on quality of life (QoL).  
 
Patients and methods 
 
Screening 
In the southern part of the Netherlands, BC screening started in 1991, and full 
coverage was reached in 1996. Since then, the attendance rate has remained 
about 80 per cent. Women aged 50-75 years receive a standard invitation every 
two years. The invitation includes a set date and time, and an information leaflet. 
This leaflet informs women how the screening mammogram is done. Since 2006 
information has also been included about the number of women who are referred 
to the hospital because of abnormalities on the mammogram. 
 
Patients 
Women who were referred to the outpatient clinic of the St. Elisabeth Hospital 
(patient accrual started September 2002), Maasland Hospital (since August 2004) 
and Jeroen Bosch Hospital (since January 2006), with an abnormality on a 
screening mammogram were asked to participate. They were included in a 
prospective follow-up study concerning QoL in women with early-stage BC, and 
the influence of surgery and personality on QoL. This study was approved by the 
Medical Ethics Board of the St. Elisabeth Hospital as primary research institute. 
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information has also been included about the number of women who are referred 
to the hospital because of abnormalities on the mammogram. 
 
Patients 
Women who were referred to the outpatient clinic of the St. Elisabeth Hospital 
(patient accrual started September 2002), Maasland Hospital (since August 2004) 
and Jeroen Bosch Hospital (since January 2006), with an abnormality on a 
screening mammogram were asked to participate. They were included in a 
prospective follow-up study concerning QoL in women with early-stage BC, and 
the influence of surgery and personality on QoL. This study was approved by the 
Medical Ethics Board of the St. Elisabeth Hospital as primary research institute. 
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Up to January 2007, 609 women were included, of whom 385 had an abnormal 
screening mammogram. Eventually 152 of these 385 women were diagnosed with 
breast cancer (BC group), whereas 233 women had a false-positive mammogram 
and were diagnosed with benign breast disease after investigation (FP group). All 
women gave written informed consent before entering the study. 
 
Methods 
Two-view mammography was used at initial breast screening, whereas 
subsequently only a medio-lateral view was taken. Two radiologists trained in 
screening mammography reviewed the mammograms separately. All women with 
a mammographic abnormality (positive screening) were referred to the surgical 
outpatient clinic. A positive test was classified as true positive if BC was diagnosed 
subsequently on the basis of pathological findings after biopsy. A test was 
classified as a false-positive if no pathological evidence of BC was found.10 
Negative effects from screening were defined as all unwanted side-effects 
(physical, psychological, and economic) from the BC program. The present study 
focused on the diagnostic procedures (mammography, stereotactic and 




QoL was assessed using the World Health Organization Quality of Life 
assessment instrument 100 (WHOQOL-100)11, a cross-cultural generic multi-
dimensional questionnaire. This assessed QoL in six domains (Physical health, 
Psychological health, Level of independence, Social relationships, Environment 
and Spirituality) and a general evaluative facet (Overall QoL and general health). 
The reliability and validity of the instrument are good for women with breast 
disease.12  
Personality was assessed at baseline using the Neuroticism-Extraversion-
Openness-Five Factor Inventory (NEO-FFI)13, and the trait anxiety scale of the 
State and Trait Anxiety Inventory (STAI).14  
The NEO-FFI was developed to study an individual’s personality. Personality is 
assessed in the five domains of the five-factor-model: neuroticism, extraversion, 
openness, agreeableness and conscientiousness. The psychometric properties are 
good.13  
The STAI was originally developed to investigate anxiety phenomena in normal 
adults, but has also proven useful in medical and surgical patients. It measures two 
types of anxiety. Trait anxiety, assessed in the present study at baseline, concerns 
differences in individuals in the way they respond to stressful situations. State 
ABNORMAL	  SCREENING	  MAMMOGRAM	  AND	  QOL	   23	  
    
	  
anxiety was assessed at each measurement and refers to the amount of stress 
experienced at the moment of measurement. The psychometric characteristics of 
this questionnaire are well established.14  
Patients were also asked to complete questions concerning demographic factors 
such as age, marital status, education, and socioeconomic status. Clinical data 
were obtained from the medical records.  
 
Statistical procedures 
One-way ANOVA, t-tests, and chi-square tests were used to compare baseline 
characteristics in the BC and FP groups. The predictors of overall QoL (dependent 
variable) one, three, six and twelve months after diagnosis were found using the 
demographic (block 1), clinical (block 2), and personality characteristics (block 3) 
as independent variables in multivariable regression analysis. Variables that 
significantly influenced overall QoL were then dichotomized (high score or not) and 
subsequently entered into logistic regression analysis to provide the odds ratio for 
a low overall QoL score.  
A general linear model for repeated measures (GLM) was used to examine scores 
on overall QoL and state anxiety over time in both BC group and the FP group, and 
also according to trait anxiety in combination with the result of the screening 
mammogram (BC or FP). In each analysis the characteristics on which the groups 
appeared to differ at baseline were used as co-variables. Eta squared is an effect 
size that can be derived from the output of the GLM. An eta squared value 
between 0.01 and 0.06 denotes a small effect, between 0.06 and 0.13 a moderate 
effect, and 0.14 or higher a large effect.15 To reach a statistical power of 0.80, at 
least 55 women were needed in each group, based on an expected moderate 
effect size. When differences were found in the GLM between groups, one-way 
ANOVA was used to examine QoL differences between groups at one particular 
measurement time. Again the characteristics on which the two groups differed at 
baseline were incorporated in the analyses as co-variables. A p-value < 0.05 was 
considered statistically significant. All analyses were performed with the Statistical 
Package for Social Sciences® version 16.0 (SPSS, Chicago, Illinois, USA). 
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At baseline, before the abnormality on the screening mammogram was defined as 
either BC or FP, the two patient groups differed in age, with those in the FP group 
being significantly younger (mean age 57 versus 60 years; p<0.001). Other 
demographic characteristics were comparable (Table 1). The mammographic 
abnormality was significantly larger in the BC group (mean 17.4 versus 9.9 mm; 
p<0.001). There were no significant differences in personality between the two 
groups; however, scores on state anxiety at baseline were significantly different, 
with the BC group expressing more anxiety (mean 48.3 versus 40.1; p<0.001). 
 
Table 1 Demographic, personality, and psychological characteristics in women with a mammographic 
abnormality: breast cancer (BC) or false-positive (FP) 
 BC N=152 FP N=233 P 
Demographics    
Age (years) * 60.2 (7.1) 57.3 (6.9) <0.001 
Partner 122 (82.5) 200 (87) 0.288 
Children 117 (77) 170 (73.3) 0.556 
Education (years) 
          0-10  
          10-14  










Tumour size on radiology (mm) * 17.4 (13.8) 9.9 (10.6) <0.001 
    
Personality     
Neuroticism * 30.0 (7.2) 31.1 (6.6) 0.133 
Extraversion * 40.8 (5.4) 39.7 (5.6) 0.720 
Openness * 35.6 (6.0) 36.6 (5.1) 0.086 
Agreeableness * 43.9 (4.1) 43.5 (4.1) 0.389 
Conscientiousness * 45.7 (5.4) 45.4 (4.7) 0.562 
Trait anxiety * 39.6 (11.2) 38.4 (10.6) 0.318 
    
Psychological factors     
Quality of life * 15.6 (2.4) 15.6 (2.6) 0.733 
State anxiety * 48.3 (13.9) 40.1 (12.9) <0.001 
Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.).  
Significant p-value presented in bold.  
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Significantly more diagnostic procedures (including biopsies) were needed in the 
FP group to reach a final diagnosis (p<0.001). In the BC group 130 patients (86 
per cent) required three diagnostic procedures, and 14.5 per cent required four. In 
the FP group 75 patients (32 per cent) required more than three procedures. Only 
66 women (29 per cent) in the FP group could be reassured after a repeat 
mammogram; all other women needed at least one core biopsy and in 18 (8 per 
cent) ultimately needed excision biopsy to arrive at the diagnosis.  
 
Table 2 Quality of life and state anxiety for women with an abnormal mammogram over time since 
diagnosis 
 Quality of life State Anxiety 
 BC FP BC FP 
Baseline 16.0 (2.4) 15.2 (3.1) 48.1 (14.8) 39.0 (11) 
 1 month 15.4 (2.6) * 15.5 (2.8) 37.0 (11.1) * 33.4 (10.0) * 
3 months 15.7 (2.5) 15.2 (3.0) 36.6 (12.8) 35.0 (11.1) 
6 months 15.7 (2.5) 15.4 (2.8) 35.7 (12.7) 33.3 (11.5) 
1 year 15.9 (2.5) 15.3 (2.8) 35.4 (11.5) 33.4 (10.9) 
Values are mean (s.d.). BC = breast cancer group; FP = false-positive group. Overall, quality of life  
and state anxiety values were higher in the BC than in the FP group (both p<0.001); * p<0.001 versus 
baseline. 
 






R2 Beta P 
1 month FP Trait anxiety 0.43 -0.656 <0.001 












































1 year FP Trait anxiety 0.40 -0.679 <0.001 








BC = breast cancer group; FP = false-positive group. R2 = the proportion of variance in the scores of the 
dependent variable explained by the independent variable (1.00 = 100%); a negative Beta value means 
that a higher score for the independent variable will result in a lower score for the dependent variable.  
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After the diagnosis, 105 women (45 per cent) in the FP group did not need (or 
want) a follow-up; 100 (43 per cent) came only once to the outpatient clinic in the 
following year and the remaining 28 came up to eight times. 
There was a significant reduction in QoL between baseline and the measurement 
one month after diagnosis and surgery in the BC group. The scores on state 
anxiety were significantly reduced for both the FP and the BC groups between 
baseline and one month later (Table 2). Scores on state anxiety also differed 
significantly between the two groups at baseline and one month after surgery, with 
the BC group scoring higher (more anxious). 
Regression analyses showed that the factors influencing QoL scores differed 
between the two patient groups. In the FP group, trait anxiety was the most 
important factor; it explained up to 55 per cent of the variance in QoL scores. In the 
BC group, neuroticism and state anxiety were the two significant influencing 
factors; neuroticism was responsible for up to 7 per cent of the effect, whereas 
state anxiety explained up to 46 per cent of the variance in scores (Table 3). 
 
 
Figure 1 Overall quality of life and anxiety levels (general mean scores) in patients with breast cancer 
(BC) or a false-positive screening mammogram (FP) according to the level of personality characteristic 
trait anxiety at time intervals after diagnosis 
Measurement moments: 1 = baseline, 2 = 1 month, 3 = 3 months, 4 = 6 months, 5 = 12 months. 
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When the women were divided into four groups based on the diagnosis (FP or BC) 
and their scores on the personality characteristic trait anxiety (high or low), it was 
found that the women with a high trait anxiety scored significantly lower on QoL 
and higher on state anxiety, irrespective of the diagnosis (p<0.001; Fig. 1). The Eta 
squared value for QoL was 0.27 and for state anxiety was 0.44. Although Figure 1 
suggested a significant difference in QoL between the FP and BC groups with high 




Discussion concerning the benefits and harms of BC screening is ongoing.16,17 
Some women truly benefit from early detection, whereas others experience harm 
and unnecessary anxiety. Thus, the decision to participate in a screening program 
requires balanced information about its potential benefits and dangers.2,18 
In this study women scored high on state anxiety before diagnosis was known. 
One month after diagnosis, state anxiety reduced both in the women who turned 
out to have a false-positive mammogram and in those diagnosed with BC. The 
absolute decrease in scores was higher in the BC group. However, state anxiety 
was still the most important factor influencing overall QoL scores in the BC group. 
It was responsible for up to 46 per cent of the variance in scores. In the FP group, 
personality, and particularly the personality characteristic trait anxiety, was the 
most significant factor influencing overall QoL. Thus, anxious women fared worse 
after a false-positive result, an effect that lasted for at least one year after the 
screening mammogram.  
In the Netherlands the recall rates after screening vary from 0.89 to 1.12 per cent. 5 
This is very low in comparison with screening programs in other countries, which 
have reported recall rates of 2-5 per cent.5,19 After recall, 60.5 per cent of the 
women were diagnosed with benign breast disease in the present study.  
Factors that affect the risk of a false-positive mammogram result in general are the 
frequency of screening tests and fear of litigation; some authors in the United 
States estimate the risk of a false-positive test to be almost 50 per cent for women 
undergoing ten tests in 10 years.8  
In a recent study it was calculated that women aged 50-51 years had a cumulative 
risk of 21 per cent for a false-positive recall with biannual screening over two 
decades.20 Another study found that, for every 1000 women screened over 10 
years, up to 25 per cent received an abnormal result, with 6.5 per cent of these 
women undergoing at least one biopsy.21 In the present study 66 women (29 per 
cent) needed only a repeat mammogram, whereas 167 (72 per cent) underwent at 
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least one core biopsy and 18 women (8 per cent) eventually needed an excision 
biopsy to achieve a benign diagnosis.   
In the information leaflet that is included with the invitation for BC screening it is 
mentioned that about 60 per cent of the women who are recalled will have a 
benign diagnosis. This value has been included in the information only since 2006. 
However, the diagnostic (sometimes invasive) procedures needed to reach this 
diagnosis are not mentioned either in the information leaflet or on the internet 
information site. In particular, there is no reference to any negative psychological 
effects this process may have.   
Several studies have reported that most women with a false-positive result were 
glad they had been tested, felt that they were at high risk, and intended to be 
tested again.2,22,23 Most of the fear caused by the positive test was removed by the 
result of the confirmatory tests. However, in that study the participants were 
interviewed by telephone and the questionnaires were completed some time after 
the women had been informed of the final diagnosis. Only one study reported 
concern during the year after the mammogram, with subsequent outpatient visits.24 
In the present study 55 per cent of the FP group returned to the outpatient clinic in 
the first year after the screening, some up to eight times. Some of these visits were 
requested by the treating physician, but many follow-up visits were instigated by 
the women themselves. The visits requested by a doctor might have influenced the 
QoL and state anxiety; however, with the exception of overall QoL six months after 
diagnosis, no differences were found between women who visited the outpatient 
clinic and women who did not, in terms of overall QoL and state anxiety (data not 
shown). This implies that the anxiety and lower QoL experienced by women with a 
false-positive mammogram were solely due to the recall after screening and the 
subsequent diagnostic procedures.  
Women often overestimate their risk of BC and the benefits of screening, and are 
not aware of the possible dangers.25 The material provided by professional groups 
and governmental institutions is often in favour of screening and not always 
objective. A cross-sectional study of 27 websites by interest groups in different 
countries found that the most important dangers of screening – overdiagnosis and 
overtreatment – were underexposed subjects.26 
Women deserve more balanced information to help them chose whether or not to 
accept the invitation for screening mammography. This should not only focus on 
the supposed benefits, but should include potential side-effects such as increased 
feelings of anxiety.  
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least one core biopsy and 18 women (8 per cent) eventually needed an excision 
biopsy to achieve a benign diagnosis.   
In the information leaflet that is included with the invitation for BC screening it is 
mentioned that about 60 per cent of the women who are recalled will have a 
benign diagnosis. This value has been included in the information only since 2006. 
However, the diagnostic (sometimes invasive) procedures needed to reach this 
diagnosis are not mentioned either in the information leaflet or on the internet 
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false-positive mammogram were solely due to the recall after screening and the 
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The aim of this study was to analyse the possible negative psychological 
consequences of a false-positive screening mammogram. We compared anxiety 
evoked by first time (FSM) versus repeat screening mammogram (RSM).  
 
Methods  
Between September 2002 and January 2010 women with an abnormality on a 
screening mammogram were included in our study. Questionnaires examining trait 
and state anxiety, depressive symptoms and quality of life (QoL), were completed 
prior to the diagnosis and during follow-up until 12 months.  
 
Results 
No differences in anxiety, depressive symptoms, and QoL were found between 
FSM (N=186) or RSM (N=296) groups. All women experienced high anxiety before 
diagnosis was known. High trait anxiety was predictive for more anxiety, 
depressive symptoms, and lower QoL. Women with low score on trait anxiety were 
more momentary anxious in FSM group compared with RSM group (p=0.048).  
 
Conclusions 
Negative psychological consequences after a false-positive screening 
mammogram are seen in all women. These effects are strengthened by personality 
and timing of the screening mammogram. All women should receive correct 
information concerning the negative psychological effects and should be offered 
psychosocial support if needed.  
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Breast cancer (BC) screening is likely to reduce BC mortality, a reasonable 
estimate is a 15 per cent relative reduction or a 0.05 per cent absolute reduction.1 
However, the adverse consequences of screening such as false-positive findings 
are the reason for the ongoing debate whether the advantages of the screening 
program outweigh the disadvantages.1   
In the Netherlands, the attendance rate of the BC screening program is 
approximately 80 per cent. The recall rate is 1 per cent, with an overall cancer 
detection rate of 5.1 per 1000 women.2,3,4 The percentage of women with at least 
one false-positive result after a screening mammogram every two years is 
estimated to be 49 per cent after ten mammograms in the United States.5 Women 
who receive false-positive results after a screening mammogram report more 
anxiety and distress in general and specifically concerning the possibility of having 
BC.1,6-11 Even though this level of anxiety diminishes after the diagnostic process is 
completed, a significant amount of women with the diagnosis benign breast 
disease is not completely reassured.12,13 Also, women with benign breast disease 
undergoing breast biopsy or fine needle aspiration report higher levels of stress 
and anxiety before biopsy and still several months after the additional 
investigations.14,15 A decrease in quality of life (QoL) with an increase in anxiety 
was also seen in women undergoing additional investigations after an abnormal 
screening mammogram.12 A recent review confirmed this impact of BC screening 
on QoL.16 Anxious women again experience adverse psychological consequences 
just before being invited for their next breast screening appointment.17,18 A recent 
review reported several possible factors predictive for psychological outcomes 
after a false-positive mammogram. The factors associated with more negative 
psychological outcomes were younger age, lower level of education, more anxious 
at the previous screening round, and a previous false-positive mammogram.6  
The aim of this study was to analyse the possible negative psychological 
consequences of the screening mammogram program and the impact of these 
psychological consequences on QoL. We were especially interested in the timing 
of the screening mammogram. We hypothesized that when women attend the 
screening program for the first time and are referred because of an abnormal 
mammogram they may express more anxiety and depressive symptoms and 
experience a more pronounced decrease in QoL compared with women who have 
attended the program before without any problems and are thus ‘more 
experienced’. As previously shown, these effects are expected to be negatively 
influenced by personality, i.e. trait anxiety.12 Contrary to most studies concerning 
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this subject, in this prospective, longitudinal study women completed the first set of 
questionnaires before any diagnostic procedures were performed.  
 
Patients and methods 
 
Screening 
Since 1990 in the Netherlands BC screening is offered every two years to women 
in the age between 50 and 75 years. Every year one million women receive an 




In the period between September 2002 and January 2010 women with an 
abnormality on a screening mammogram referred to the St. Elisabeth Hospital, the 
Maasland Hospital, the Jeroen Bosch Hospital, the Catharina Hospital, the Viecuri 
Medical Center, or the Medical Center Alkmaar (The Netherlands) were invited to 
participate in our study.  
Two-view mammography was used at initial BC screening. All women with an 
abnormal screening mammogram were referred to the surgical outpatient clinic. A 
positive screening mammogram was classified as true positive if BC diagnosis was 
confirmed with biopsy. A false-positive screening mammogram was defined as true 
negative if the mammogram and/or ultrasound of the breast and/or biopsy were 
excluding the diagnosis BC.  
The present study is part of a larger study focusing on the impact of personality 
and QoL on morbidity, mortality, and health care consumption in women with BC 
and benign breast disease. Women with recurrent benign breast disease or BC, 




Approval of the study protocol was given by the Medical Ethical Committee of the 
primary research hospital, being the St. Elisabeth Hospital. When women were 
invited to participate in the study and completed the first set of questionnaires, no 
additional diagnostic procedures were done yet and the diagnosis was still 
unknown. All participants gave written informed consent. 
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Questionnaires 
Questionnaires were completed at baseline before diagnosis is known, and one, 
three, six and twelve months after the definitive diagnosis. The questionnaires 
used assessed personality (NEO-FFI, STAI-Trait), depressive symptoms (CES-D), 
momentary anxiety (STAI-State) and QoL (WHOQOL-Bref). 
 
The Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI) is 
developed to assess the Five Factor Personality Model: neuroticism, extraversion, 
openness to new experiences, agreeableness and conscientiousness.19,20 The 
psychometric properties are good.19 In the present study the questionnaire was 
completed at baseline and only the 12-items for neuroticism were used for the 
analyses. A high score for neuroticism was defined as a score above 38 in 
concordance with the manual.19 
The State and Trait Anxiety Inventory (STAI) measures trait and state anxiety.21,22 
Trait anxiety concerns differences in individuals in the disposition to respond to 
stressful situations with varying amounts of stress. State anxiety is a momentary 
emotional condition characterized by subjective feelings of apprehension and 
tension, and heightened autonomic nervous system activity. This may vary in 
intensity and fluctuate over time.21 The short version of the STAI-Trait and STAI-
State was used.23,24,25 The 6-items state scale was assessed at all measurement 
moments and the 10-items trait scale at baseline. High trait anxiety was defined as 
a score above 22, and high state anxiety was defined as a score above 14 
according to the recommendations in the manual. The psychometric characteristics 
of this short version are well established and considered good.23,24,25 
The Center for Epidemiological Studies-Depression Scale (CES-D) was used to 
assess depressive symptoms at all measurement moments. It measures both the 
presence and the degree of depressive symptoms with a 16-items scale. The 
reliability and validity appear to be good.26,27 
The World Health Organization Quality of Life assessment instrument-Bref 
(WHOQOL-Bref) is a generic, cross-culturally developed comprehensive measure 
of QoL. It is the short version of the WHOQOL-100 questionnaire.28,29 The 
WHOQOL-Bref measures QoL in four domains (Physical health, Psychological 
health, Social relationships and Environment) and the facet Overall QoL and 
general health. The psychometric properties of the WHOQOL-Bref are good in 
women with benign breast disease.30 The WHOQOL-Bref was completed at two 
moments: at baseline and after 12 months.  
At baseline, women were also asked to complete a questionnaire concerning 
demographic characteristics, such as age, paid work, children, marital status, and 
3
34	   CHAPTER	  3	  
	  
	  
this subject, in this prospective, longitudinal study women completed the first set of 
questionnaires before any diagnostic procedures were performed.  
 
Patients and methods 
 
Screening 
Since 1990 in the Netherlands BC screening is offered every two years to women 
in the age between 50 and 75 years. Every year one million women receive an 




In the period between September 2002 and January 2010 women with an 
abnormality on a screening mammogram referred to the St. Elisabeth Hospital, the 
Maasland Hospital, the Jeroen Bosch Hospital, the Catharina Hospital, the Viecuri 
Medical Center, or the Medical Center Alkmaar (The Netherlands) were invited to 
participate in our study.  
Two-view mammography was used at initial BC screening. All women with an 
abnormal screening mammogram were referred to the surgical outpatient clinic. A 
positive screening mammogram was classified as true positive if BC diagnosis was 
confirmed with biopsy. A false-positive screening mammogram was defined as true 
negative if the mammogram and/or ultrasound of the breast and/or biopsy were 
excluding the diagnosis BC.  
The present study is part of a larger study focusing on the impact of personality 
and QoL on morbidity, mortality, and health care consumption in women with BC 
and benign breast disease. Women with recurrent benign breast disease or BC, 




Approval of the study protocol was given by the Medical Ethical Committee of the 
primary research hospital, being the St. Elisabeth Hospital. When women were 
invited to participate in the study and completed the first set of questionnaires, no 
additional diagnostic procedures were done yet and the diagnosis was still 
unknown. All participants gave written informed consent. 
 
SCREENING	  AND	  STATE	  ANXIETY	   35	  
    
	  
Questionnaires 
Questionnaires were completed at baseline before diagnosis is known, and one, 
three, six and twelve months after the definitive diagnosis. The questionnaires 
used assessed personality (NEO-FFI, STAI-Trait), depressive symptoms (CES-D), 
momentary anxiety (STAI-State) and QoL (WHOQOL-Bref). 
 
The Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI) is 
developed to assess the Five Factor Personality Model: neuroticism, extraversion, 
openness to new experiences, agreeableness and conscientiousness.19,20 The 
psychometric properties are good.19 In the present study the questionnaire was 
completed at baseline and only the 12-items for neuroticism were used for the 
analyses. A high score for neuroticism was defined as a score above 38 in 
concordance with the manual.19 
The State and Trait Anxiety Inventory (STAI) measures trait and state anxiety.21,22 
Trait anxiety concerns differences in individuals in the disposition to respond to 
stressful situations with varying amounts of stress. State anxiety is a momentary 
emotional condition characterized by subjective feelings of apprehension and 
tension, and heightened autonomic nervous system activity. This may vary in 
intensity and fluctuate over time.21 The short version of the STAI-Trait and STAI-
State was used.23,24,25 The 6-items state scale was assessed at all measurement 
moments and the 10-items trait scale at baseline. High trait anxiety was defined as 
a score above 22, and high state anxiety was defined as a score above 14 
according to the recommendations in the manual. The psychometric characteristics 
of this short version are well established and considered good.23,24,25 
The Center for Epidemiological Studies-Depression Scale (CES-D) was used to 
assess depressive symptoms at all measurement moments. It measures both the 
presence and the degree of depressive symptoms with a 16-items scale. The 
reliability and validity appear to be good.26,27 
The World Health Organization Quality of Life assessment instrument-Bref 
(WHOQOL-Bref) is a generic, cross-culturally developed comprehensive measure 
of QoL. It is the short version of the WHOQOL-100 questionnaire.28,29 The 
WHOQOL-Bref measures QoL in four domains (Physical health, Psychological 
health, Social relationships and Environment) and the facet Overall QoL and 
general health. The psychometric properties of the WHOQOL-Bref are good in 
women with benign breast disease.30 The WHOQOL-Bref was completed at two 
moments: at baseline and after 12 months.  
At baseline, women were also asked to complete a questionnaire concerning 
demographic characteristics, such as age, paid work, children, marital status, and 
36	   CHAPTER	  3	  
	  
	  
education. The medical data concerning patient and mammogram characteristics 
were obtained from the medical records.  
 
Statistical procedures 
For examining differences between the two groups, first screening mammogram 
(FSM) or repeat screening mammogram (RSM), with regard to baseline personality 
and demographic characteristics chi-square tests and t-tests were used. 
General linear model for repeated measures was used to examine scores on state 
anxiety, depressive symptoms, and QoL over time (i) in the two groups FSM and 
RSM, and (ii) in patients with a high or not-high score on trait anxiety in the FSM 
and RSM groups.  
The predictors for state anxiety (dependent variable), depressive symptoms 
(dependent variable) and overall QoL (dependent variable) were found using the 
demographic (block 1) and personality characteristics (block 2) as independent 
variables in a multivariate linear regression analysis.  
A p-value < 0.05 was considered statistical significant. All analyses were 
performed with the Statistical Package for Social Sciences® version 15.0 (SPSS, 




In total 818 women were referred after an abnormal screening mammogram, in 
527 (64 per cent) women benign breast disease was diagnosed. In 188 women 
with an abnormal result it was their first screening mammogram. In 30 women the 
timing of the screening mammogram was not known. Therefore, these women 
were excluded. At baseline, 15 of the 527 women did not fully or correctly complete 
the questionnaires and were excluded from further analysis.  
At baseline there were no differences between the FSM group (N=186) and the 
RSM group (N=296) concerning demographics and personality, except for paid 
work and age. In the FSM group more women had paid work (p<0.001) and 
women in the RSM group were older (p<0.001; Table 1). 
State anxiety scores showed the same pattern in the FSM and RSM groups. Both 
groups scored high before diagnosis and these scores significantly diminished 
after one, three and six months compared with baseline scores (p<0.001; Fig. 1).  
Concerning depressive symptoms in the FSM and RSM groups a similar pattern 
was seen. Women scored high on depressive symptoms before diagnosis. These 
scores significantly decreased after one, three and six months in both groups 
(p<0.001). Again no differences were found between the groups.  
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When the women were divided in four groups based on first or repeat screening 
mammogram and their scores for trait anxiety at baseline (high versus not-high), it 
was found that women with a high score on trait anxiety (N=115) scored higher on 
state anxiety at baseline and during follow-up, irrespective of the group they were 
in (FSM or RSM) (p<0.001; Fig. 2). Women in the FSM group with a score not-high 
on trait anxiety (N=141) scored significantly higher on state anxiety at baseline 
compared with the RSM group not-high on trait anxiety (N=226), 12.5 versus 11.7 
respectively (p=0.048). Women with a high score on trait anxiety were compared 
with women with a normal score with regard to demographics. A lower level of 
education was more often seen in women with high trait anxiety (p=0.001). With 
regard to depressive symptoms women with a high score on trait anxiety scored 
higher on depressive symptoms at all measurement moments, irrespective of the 
moment of the false-positive mammogram (p<0.001; Fig. 3).  
 
Table 1 Demographic, personality and psychological characteristics at baseline for first (FSM) or repeat 
screening mammogram (RSM) 
 FSM N=186 RSM N=296 P 
Demographics    
Age (years) * 50 (0.8) 61 (5.9) <0.001 
Partner 163 (88) 254 (86) 0.145 
Children 158 (85) 275 (93) 0.082 
Education low/moderate 156 (84) 248 (84) 0.345 
Paid work 141 (76) 106 (36) <0.001 
    
Personality    
Trait anxiety score * 18.0 (5.4) 18.2 (5.3) 0.663 
High trait anxiety 45 (24) 70 (24) 0.856 
Neuroticism score * 28.5 (7.5) 29.2 (6.8) 0.301 
High neuroticism 12 (6) 28 (9) 0.216 
    
Psychological factors    
State anxiety * 13.3 (4.0) 12.8 (4.2) 0.209 
Quality of life * 7.7 (2.7) 7.8 (2.4) 0.634 
Depressive symptoms * 8.9 (8.5) 9.0 (8.4) 0.836 
Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.).  
Significant p-value presented in bold. 
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education. The medical data concerning patient and mammogram characteristics 
were obtained from the medical records.  
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When the women were divided in four groups based on first or repeat screening 
mammogram and their scores for trait anxiety at baseline (high versus not-high), it 
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Figure 1 and 2 State anxiety per diagnosis and per diagnosis and score on trait anxiety  
FSM = first screening mammogram, RSM = repeat screening mammogram, NHTA = not-high trait 
anxiety, HTA = high trait anxiety 
 
  Fig. 1 
  
  Fig. 2 
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Figure 3 and 4 Depressive symptoms and quality of life per diagnosis and score on trait anxiety 
FSM = first screening mammogram, RSM = repeat screening mammogram, NHTA = not-high trait 
anxiety, HTA = high trait anxiety  
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Concerning the scores of the four domains QoL and the overall QoL there were no 
differences between the FSM and the RSM groups found at baseline and at 12 
months follow-up. Women in the FSM group who did not score high on trait anxiety 
scored lower on the domain social QoL compared with the women who did not 
score high on trait anxiety in the RSM group (p=0.047). Scores on overall QoL and 
the four domains QoL were consistently lower in women with a high score on trait 
anxiety in both groups at baseline (p<0.001) and at 12 months (p=0.015; Fig. 4).  
Regression analyses revealed that the most important factor of influence was trait 
anxiety in both groups considering state anxiety and depressive symptoms and 
QoL. In the FSM group other factors of influence were neuroticism, age and marital 
status and in the RSM group those factors were neuroticism, paid work and 
education, but their influence was small compared with the impact of trait anxiety 
(Table 2). 
 
Table 2 Regression analyses for state anxiety, depressive symptoms and quality of life (QoL) as 
dependent variables 




R2 Beta P 
State anxiety  
6 months 
FSM Trait anxiety 0.18 0.419 <0.001 
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Psychological domain QoL 
12 months 
FSM Trait anxiety 0.23 -0.479 <0.001 
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FSM = first screening mammogram; RSM = repeat screening mammogram. R2 = percentage of 
variance in the scores of the dependent variable explained by the independent variable (1.00 = 100%); 
Beta: a negative Beta means that a higher score on the independent variable will result in a lower score 
of the dependent variable.  
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The adverse psychological consequences caused by false-positive findings after a 
screening mammogram are an important reason for the ongoing debate 
concerning the BC screening program.1 Therefore, it is important not only to inform 
women properly concerning pro’s and con’s of screening but also to identify those 
women at risk for adverse psychological consequences after a false-positive 
mammogram.  
The aim of the present study was to analyse the effect of the timing of an abnormal 
screening mammogram (first time versus repeat mammogram). A difference in 
anxiety, depressive symptoms, and QoL in favor of women with previous 
experience with screening mammograms was expected. Also, an influence of trait 
anxiety and neuroticism was expected. In our study no significant differences were 
observed between the two groups (FSM and RSM) on anxiety, depressive 
symptoms or QoL. All women experienced high anxiety before diagnosis was 
known.  
However, when women were divided into four groups based on timing of the 
mammogram and their scores on the personality characteristic trait anxiety a 
significant difference in state anxiety was found. Women in the FSM group who 
were not prone to anxiety did respond with more anxiety after a false-positive 
mammogram. Apparently these women are insufficiently prepared for the 
possibility of a false-positive mammogram. Women not prone to anxiety who had 
experience with the screening program did experience lower levels of anxiety. 
A high score on trait anxiety correlated significantly with high scores on state 
anxiety and depressive symptoms, irrespective of the experience of the woman 
with the screening program. Concerning neuroticism a similar pattern was seen for 
state anxiety, depressive symptoms and QoL as for trait anxiety. Almost all women 
with a high score on neuroticism scored high on trait anxiety. Anxiety can be 
considered as a part of the domain neuroticism, but can also be defined 
individually. Therefore, the same effects seen in women scoring high on 
neuroticism and trait anxiety can be explained by the correlation between 
neuroticism and anxiety. It is known that women’s daily activities and QoL are 
affected by the higher levels of anxiety.16  
It is possible that our results are an underestimation. Women with a high score on 
trait anxiety at baseline were more frequently not able to complete all 
questionnaires during follow-up. Therefore, we can assume that our results would 
have been even more convincing if those women had returned all questionnaires.  
This present study confirms previous findings in which women with a false-positive 
screening mammogram experienced for at least one year a low QoL and feelings 
3
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affected by the higher levels of anxiety.16  
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trait anxiety at baseline were more frequently not able to complete all 
questionnaires during follow-up. Therefore, we can assume that our results would 
have been even more convincing if those women had returned all questionnaires.  
This present study confirms previous findings in which women with a false-positive 
screening mammogram experienced for at least one year a low QoL and feelings 
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of anxiety, especially when they score high on trait anxiety.12 The present study is 
performed in more hospitals (six versus three) and more women were included 
(482 women versus 233 women) than in our previous study. Therefore, we can 
conclude that the previous results are validated by this study. Contrary to most 
studies concerning this subject, in our study the first questionnaires were 
completed before diagnosis was known, which makes our results even more 
consistent.  
In the Netherlands, annually around 900.000 women undergo a screening 
mammogram with a recall rate of 1 per cent and a false-positive rate of 66 per 
cent.4 Concerning the comparable false-positive rate of 64 per cent in our study 
group with 115 women (24 per cent) scoring high on trait anxiety, these rates imply 
a large group of women who are at risk for adverse psychological consequences. 
In the United States the recall rate is 11 per cent after a first screening 
mammogram and 7 per cent after a subsequent screening mammogram.31 
Concerning this higher recall rate compared with the Dutch situation, adverse 
psychological consequences after a false-positive screening mammogram are 
expected to be an even more serious problem in the United States.  
Recently several publications have been addressing the screening controversy by 
questioning the benefits and harms of the BC screening program.1,32-38 The 
decision to participate in the BC screening program is based upon information in 
favor of screening without mentioning the risk for overdiagnosis and overtreatment 
and the possible adverse psychological consequences.1,35-37,39,40 In the present 
study these adverse psychological consequences are confirmed. The levels of 
anxiety found in chronically anxious women were in 79 per cent abnormal (with a 
score above 14), whereas in 30 per cent of the women without high trait anxiety 
abnormal anxiety scores were found (data not shown).23 Therefore, this high 
anxiety cannot be considered as a normal response to screening, in the sense that 
not every woman responds with elevated anxiety. In addition, in our previous study 
55 per cent of the women frequently visited the outpatient clinic in the first year 
after their false-positive screening mammogram.12 Apparently, these women need 
more reassurance to confirm that their diagnosis is not BC. We recommend that 
every woman should be offered a psychometric test at the time of recall after an 
abnormal screening mammogram. Those women with high state anxiety should be 
offered psychosocial interventions that focus on learning how to cope with these 
stressful events.  
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This study reveals that the adverse psychological consequences after a false-
positive screening mammogram are seen in all women. These effects are 
influenced by personality and by the timing of the screening mammogram. Women 
participating in the screening mammogram program should receive correct and 
complete information every screening round before they decide to participate. This 
information should mention the risk of experiencing adverse psychological 
consequences and every woman should be offered psychosocial support when 
necessary. 
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Being recalled for further diagnostic procedures after an abnormal screening 
mammogram (ASM) can evoke a high state anxiety with lowered quality of life 
(QoL). We examined whether these adverse psychological consequences are 
found in all women with benign breast disease (BBD) or are particular to women 
referred after ASM. In addition, the influence of the anxiety as a personality 
characteristic (trait anxiety) was studied.  
 
Methods  
Between September 2002 and February 2010 we performed a prospective 
longitudinal study in six Dutch hospitals. Women referred after ASM or with a 
palpable lump in the breast (PL), who were subsequently diagnosed with BBD, 
were included. Prior to diagnosis (at referral) and during follow-up, questionnaires 
were completed examining trait anxiety (at referral), state anxiety, depressive 
symptoms (at referral, one, three and six months after diagnosis), and QoL (at 
referral and 12 months).  
 
Results  
Women referred after ASM (N=363) were compared with women with PL (N=401). 
A similar state anxiety score was found in both groups, but a lower psychological 
QoL score at 12 months was seen in the ASM group. In women with not-high trait 
anxiety those in the ASM group were more anxious with more depressive 
symptoms at referral, and reported impaired psychological QoL at referral and at 
12 months compared with the PL group. No differences were found between ASM 
and PL in women with high trait anxiety, but this group scored unfavorably on 




ASM evokes more anxiety and depressive symptoms and lowered QoL compared 
with women referred with PL, especially in women who are not prone to anxiety. 
Women should be fully informed properly about the risks and benefits of breast 
cancer screening programs. We recommend identifying women at risk of reduced 
QoL using a psychometric test.    
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Breast cancer (BC) is the most common cancer among women. In the western 
world one in eight women is at risk of developing BC.1,2 However, the majority of 
women visiting the surgical outpatient clinic with breast problems, such as a 
palpable lump (PL) or an abnormal screening mammogram (ASM), are diagnosed 
with benign breast disease (BBD).3 During the investigation of breast symptoms, 
women experience increased anxiety and distress.4-6 Even after a diagnosis of 
BBD is made, these symptoms persist in a proportion of women.4 Women with 
BBD diagnosed after an ASM report ongoing anxiety7-9 with lowered quality of life 
(QoL).10,11 In chronically anxious women (i.e. with high trait anxiety) these 
psychological effects are heightened.6,10,12 Trait anxiety refers to relatively stable 
individual differences in anxiety proneness.13  
Thus, it is important to evaluate women diagnosed with BBD as the lack of 
reassurance after the diagnostic work-up and adverse psychological 
consequences may result in lowered QoL. Although these effects on women with 
BBD have been previously studied, a comparison between women referred after 
an ASM or with PL has not been performed before. This comparison is important in 
the context of the ongoing discussions on whether the advantages of a BC 
screening program still outweigh the disadvantages (such as the false-positive 
findings).14,15 Therefore, we examined whether all women with BBD (ASM and PL) 
experience similar levels of anxiety (state anxiety), depressive symptoms, and 
changes in QoL during and in the year following the diagnostic work-up. Women 
attending BC screening usually have no palpable lump in the breast and so are not 
expecting an ASM. We hypothesized that these women are more alarmed by being 
recalled for further diagnostic procedures and experience more adverse 
psychological effects compared with women with a PL. Based on previous studies, 
we also analysed the influence of the personality characteristic trait anxiety.10,16 
In this prospective, longitudinal study comparing ASM with PL, women completed 
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expecting an ASM. We hypothesized that these women are more alarmed by being 
recalled for further diagnostic procedures and experience more adverse 
psychological effects compared with women with a PL. Based on previous studies, 
we also analysed the influence of the personality characteristic trait anxiety.10,16 
In this prospective, longitudinal study comparing ASM with PL, women completed 
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Patients and Methods 
 
Participants 
Women referred after an ASM or with a PL were eligible for participating in this 
study. The study was conducted between September 2002 and February 2010 in 
six Dutch hospitals. The Medical Ethical Committee of the primary research 
hospital, i.e. the St. Elisabeth Hospital, Tilburg, approved the study protocol. This 
study was part of a larger study analysing the impact of personality and QoL on 
morbidity, mortality and health care consumption in breast disease. Women with 
recurrent BBD or BC, inability to read and write in Dutch, or (previous) psychiatric 
illness were excluded. When women were invited to participate in the study and 
completed the first set of questionnaires, the diagnosis was unknown. All 
participants gave written informed consent. 
Since 1990, BC screening is offered every two years to women in the age between 
50 and 75 years in the Netherlands. Every year one million women receive an 
invitation for BC screening mammogram. The overall attendance rate is 80 per 
cent.17 Two-view mammography was used at initial BC screening. All women with 
an ASM were referred to a dedicated outpatient breast clinic.  
 
Questionnaires  
Questionnaires were completed at referral (before diagnosis was known), and one, 
three, six and twelve months after diagnosis. The questionnaires assessed 
personality at referral (STAI-Trait), experienced momentary anxiety (STAI-State) 
and depressive symptoms (CES-D) at referral until six months, and QoL 
(WHOQOL-Bref) at referral and 12 months after diagnosis.  
The State and Trait Anxiety Inventory (STAI) measures two types of anxiety: trait 
and state. Trait anxiety refers to the tendency to respond to situations perceived as 
threatening with a rise in anxiety intensity. State anxiety refers to the amount of 
stress being experienced at the specific moment the measurement is made.13,18 In 
this study, the short 6-items state version and 10-items trait version of the STAI 
were used.19,20 High trait anxiety (HTA) was defined as a score greater than 22. 
The reliability and validity of the short versions are considered good.19,20  
The Center for Epidemiological Studies-Depression Scale (CES-D) was used to 
assess depressive symptoms. It measures both the presence and the degree of 
depressive symptoms. The psychometric properties are good.21,22   
The World Health Organization Quality of Life assessment instrument-Bref 
(WHOQOL-Bref) is a short version of the WHOQOL-100.23,24 The WHOQOL-Bref 
consists of questions assessing QoL within four domains (Physical health, 
Psychological health, Social relationships and Environment) and a general 
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evaluative facet (Overall QoL and general health). The psychometric properties of 
the WHOQOL-Bref have been demonstrated to be good in women with BBD.3  
Women were also asked to complete a questionnaire concerning demographic 
characteristics. The medical data concerning patient and mammography 
characteristics were obtained from the medical records.  
 
Statistical procedures 
Women who did not complete all questionnaires during follow-up, were excluded 
from further analysis and considered as drop-outs. Chi-square tests and 
independent t-tests were used to compare women in the non drop-out and drop-
out groups, and in the ASM or PL groups with regard to demographic (age, 
children, marital status, paid work, educational level) and personality (trait anxiety) 
characteristics at baseline. Differences in demographic characteristics were used 
as covariates in the subsequent analysis. 
A repeated measures general linear model was used to examine scores on state 
anxiety and depressive symptoms (at referral until six months), and QoL (at referral 
and 12 months) across time (i) in the two groups ASM or PL, and (ii) in women with 
HTA or not-high score on trait anxiety (NHTA) in ASM or PL groups. A p-value < 
0.05 was considered statistical significant. All analyses were performed with the 




During the study period 1145 women were diagnosed with BBD. During follow-up, 
381 women did not complete all questionnaires, and were excluded from further 
analysis. Women in the drop-out group were less educated (p=0.016) and scored 
higher on trait anxiety (p<0.001) compared with the group that remained in the 
study. There was no difference concerning referral after ASM or PL.  
In total, 764 women were analysed at referral, 363 women in the ASM group and 
401 in the PL group. At referral significant differences were observed concerning 
demographics between the two groups (Table 1). Women in the ASM group were 
older (p<0.001), more often had children (p=0.009), and less often had paid work 
(p<0.001). There was no difference between the two groups concerning trait 
anxiety at referral. 
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Table 1 Demographic and psychological characteristics comparing two groups: women with benign 
breast disease referred with an abnormal screening mammogram (ASM) or with a palpable lump in 
breast (PL) 
 ASM N=363 PL N=401 P  
Demographics    
Age (years) *  56.2 (6.8) 46.5 (10.9) <0.001 
Partner  308 (85) 348 (87) 0.315 
Children  315 (88) 322 (81) 0.009 
Education < 14 years 290 (80) 306 (76) 0.053 
Paid work  194 (54) 289 (72) <0.001 
    
Personality    
High score on trait anxiety  75 (21) 85 (21) 0.856 
    
Psychological factors     
State anxiety at referral * 12.9 (4.0) 12.4 (3.8)  0.074 
State anxiety 6 months * 10.4 (3.4) ° 10.4 (3.5) ° 0.988 
    
Depressive symptoms at referral * 8.8 (8.2) 7.2 (7.6) 0.007 
Depressive symptoms 6 months * 6.5 (7.0) ° 6.0 (7.1) ° 0.407 
    
General quality of life at referral * 7.9 (1.4) 7.9 (1.4) 0.732 
General quality of life 12 months * 7.7 (1.4) 8.0 (1.4) 0.385 
Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.). Significant 
p-value presented in bold. ° = scores diminished significantly at six months compared with scores at 
referral. 
 
At referral, the mean scores for state anxiety were comparable in the ASM and PL 
groups (p=0.074; Table 1). In both groups, the state anxiety scores significantly 
decreased after one month compared with the scores at referral (p<0.001; Table 
1). Concerning depressive symptoms, a higher mean score was found in ASM 
compared with PL at referral (p=0.007), in both groups scores significantly 
decreased at one month compared with the scores at referral (p<0.001; Table 1). 
After one month no differences between the two groups were found. From one 
month follow-up scores on state anxiety and depressive symptoms remained 
similar until six months in both groups (Table 1). Concerning the scores on QoL, 
there were no differences between the ASM and the PL groups at referral. At 12 
months women in the ASM group scored lower on psychological QoL (p=0.022) 
compared with the PL group. In the subanalysis, women were divided in four 
groups based on referral after ASM or with PL and their scores on trait anxiety 
(HTA or NHTA).  
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High trait anxiety 
Women with HTA (N=160) scored higher at all measurement moments on state 
anxiety, depressive symptoms, and lower on QoL compared with women with 
NHTA (p<0.001; Table 2). Within the group with HTA, women in the PL and ASM 
groups scored similar on state anxiety, depressive symptoms, and QoL (Table 2; 
Fig. 1 and 2). In both groups scores on depressive symptoms decreased 
significantly at one month compared with scores at referral (p<0.001). The only 
difference was a higher score on psychological QoL at referral in the ASM group 
(p=0.029).  
 
Not-high trait anxiety 
In women with NHTA (N=604), higher scores on state anxiety at referral were 
found in the ASM group compared with the PL group (p=0.047). During follow-up 
these scores significantly diminished after one month compared with the scores at 
referral in both groups (p<0.001; Table 2; Fig. 1), and the scores remained similar 
until six months compared with one month, without differences between groups. 
Scores on depressive symptoms were higher in ASM at referral compared with PL 
(p<0.001; Table 2; Fig. 2). In both groups scores after one month remained similar 
during follow-up. Concerning QoL women in the ASM group scored lower on 
psychological QoL at referral (p=0.022) and at 12 months (p=0.005) compared with 
the PL group.  
 
Table 2 Scores at referral and during follow-up on state anxiety, depressive symptoms, and general 
quality of life (QoL) comparing four groups based on referral after abnormal screening program (ASM) 
or with palpable lump in breast (PL) and high trait anxiety (HTA) or not-high trait anxiety (NHTA) 
 ASM N=75 PL N=85 P  
HTA *  At referral 6 months At referral 6 months  
State anxiety  15.7 (3.4) 13.1 (3.6) 15.5 (3.5) 13.2 (3.6) NS 
Depressive symptoms  15.8 (9.3) 11.4 (9.3) ° 14.7 (9.6) 12.3 (8.8) ° 
 
NS 
  At referral 12 months At referral 12 months  
General QoL  6.9 (1.4) 6.9 (1.6) 6.7 (1.5) 6.7 (1.3) NS 
      
 ASM N=288 PL N=316 P  
NHTA * At referral 6 months At referral 6 months  
State anxiety  12.2 (3.9) 9.7 (3.0) ° 11.6 (3.4) 9.7 (3.1) ° B 0.047 
Depressive symptoms  7.0 (6.8) 5.3 (5.6) 5.2 (5.4) 4.4 (5.4) B <0.001 
 
 At referral 12 months At referral 12 months  
General QoL  8.1 (1.4) 8.0 (1.3) 8.2 (1.2) 8.3 (1.2) NS 
Values are mean (s.d.). NS = not significant. ° = scores significantly changed at six months compared 
with scores at referral. * = all values in the HTA groups are significant different compared with NHTA 
groups (p<0.001). B = significant difference at referral comparing ASM and PL. 
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Table 1 Demographic and psychological characteristics comparing two groups: women with benign 
breast disease referred with an abnormal screening mammogram (ASM) or with a palpable lump in 
breast (PL) 
 ASM N=363 PL N=401 P  
Demographics    
Age (years) *  56.2 (6.8) 46.5 (10.9) <0.001 
Partner  308 (85) 348 (87) 0.315 
Children  315 (88) 322 (81) 0.009 
Education < 14 years 290 (80) 306 (76) 0.053 
Paid work  194 (54) 289 (72) <0.001 
    
Personality    
High score on trait anxiety  75 (21) 85 (21) 0.856 
    
Psychological factors     
State anxiety at referral * 12.9 (4.0) 12.4 (3.8)  0.074 
State anxiety 6 months * 10.4 (3.4) ° 10.4 (3.5) ° 0.988 
    
Depressive symptoms at referral * 8.8 (8.2) 7.2 (7.6) 0.007 
Depressive symptoms 6 months * 6.5 (7.0) ° 6.0 (7.1) ° 0.407 
    
General quality of life at referral * 7.9 (1.4) 7.9 (1.4) 0.732 
General quality of life 12 months * 7.7 (1.4) 8.0 (1.4) 0.385 
Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.). Significant 
p-value presented in bold. ° = scores diminished significantly at six months compared with scores at 
referral. 
 
At referral, the mean scores for state anxiety were comparable in the ASM and PL 
groups (p=0.074; Table 1). In both groups, the state anxiety scores significantly 
decreased after one month compared with the scores at referral (p<0.001; Table 
1). Concerning depressive symptoms, a higher mean score was found in ASM 
compared with PL at referral (p=0.007), in both groups scores significantly 
decreased at one month compared with the scores at referral (p<0.001; Table 1). 
After one month no differences between the two groups were found. From one 
month follow-up scores on state anxiety and depressive symptoms remained 
similar until six months in both groups (Table 1). Concerning the scores on QoL, 
there were no differences between the ASM and the PL groups at referral. At 12 
months women in the ASM group scored lower on psychological QoL (p=0.022) 
compared with the PL group. In the subanalysis, women were divided in four 
groups based on referral after ASM or with PL and their scores on trait anxiety 
(HTA or NHTA).  
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High trait anxiety 
Women with HTA (N=160) scored higher at all measurement moments on state 
anxiety, depressive symptoms, and lower on QoL compared with women with 
NHTA (p<0.001; Table 2). Within the group with HTA, women in the PL and ASM 
groups scored similar on state anxiety, depressive symptoms, and QoL (Table 2; 
Fig. 1 and 2). In both groups scores on depressive symptoms decreased 
significantly at one month compared with scores at referral (p<0.001). The only 
difference was a higher score on psychological QoL at referral in the ASM group 
(p=0.029).  
 
Not-high trait anxiety 
In women with NHTA (N=604), higher scores on state anxiety at referral were 
found in the ASM group compared with the PL group (p=0.047). During follow-up 
these scores significantly diminished after one month compared with the scores at 
referral in both groups (p<0.001; Table 2; Fig. 1), and the scores remained similar 
until six months compared with one month, without differences between groups. 
Scores on depressive symptoms were higher in ASM at referral compared with PL 
(p<0.001; Table 2; Fig. 2). In both groups scores after one month remained similar 
during follow-up. Concerning QoL women in the ASM group scored lower on 
psychological QoL at referral (p=0.022) and at 12 months (p=0.005) compared with 
the PL group.  
 
Table 2 Scores at referral and during follow-up on state anxiety, depressive symptoms, and general 
quality of life (QoL) comparing four groups based on referral after abnormal screening program (ASM) 
or with palpable lump in breast (PL) and high trait anxiety (HTA) or not-high trait anxiety (NHTA) 
 ASM N=75 PL N=85 P  
HTA *  At referral 6 months At referral 6 months  
State anxiety  15.7 (3.4) 13.1 (3.6) 15.5 (3.5) 13.2 (3.6) NS 
Depressive symptoms  15.8 (9.3) 11.4 (9.3) ° 14.7 (9.6) 12.3 (8.8) ° 
 
NS 
  At referral 12 months At referral 12 months  
General QoL  6.9 (1.4) 6.9 (1.6) 6.7 (1.5) 6.7 (1.3) NS 
      
 ASM N=288 PL N=316 P  
NHTA * At referral 6 months At referral 6 months  
State anxiety  12.2 (3.9) 9.7 (3.0) ° 11.6 (3.4) 9.7 (3.1) ° B 0.047 
Depressive symptoms  7.0 (6.8) 5.3 (5.6) 5.2 (5.4) 4.4 (5.4) B <0.001 
 
 At referral 12 months At referral 12 months  
General QoL  8.1 (1.4) 8.0 (1.3) 8.2 (1.2) 8.3 (1.2) NS 
Values are mean (s.d.). NS = not significant. ° = scores significantly changed at six months compared 
with scores at referral. * = all values in the HTA groups are significant different compared with NHTA 
groups (p<0.001). B = significant difference at referral comparing ASM and PL. 
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Figure 1 and 2 State anxiety and depressive symptoms per diagnosis and score on trait anxiety 
NHTA = not-high trait anxiety, PL = palpable lump, HTA = high trait anxiety, ASM = abnormal screening 
mammogram 
   




  Fig. 2  
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The discussion concerning the disadvantages of the BC screening program, such 
as false-positive findings, is still ongoing and contributing to the screening 
controversy.14,15 The adverse psychological consequences after a false-positive 
screening mammogram are already described before.7-11,16 However, to our 
knowledge, a comparison between women with BBD referred after ASM or PL has 
not yet been performed. We hypothesized that women referred after ASM 
experience more adverse psychological effects compared with women referred 
with PL.  
As previously found, the negative effects in our study were strengthened by the 
personality characteristic trait anxiety, i.e. women with HTA scored unfavourably 
on state anxiety, depressive symptoms, and QoL, compared with women not prone 
to anxiety.6,10,12 Before diagnosis was known, all women scored higher on state 
anxiety and depressive symptoms compared with one month after diagnosis, when 
women were relieved that BC was not found. In addition, we have found that within 
women not prone to anxiety, those in the ASM group were more anxious before 
diagnosis was known and experienced more depressive symptoms at referral 
compared with all women with PL. In addition, those women reported impaired 
psychological QoL at referral and one year after diagnosis compared with PL. In 
chronically anxious women higher scores on depressive symptoms at referral were 
found compared with one month after diagnosis, regardless of being referred after 
an ASM or with a PL.   
Thus, the negative impact of a false-positive screening mammogram on anxiety, 
depressive symptoms and QoL is especially found in women who do not have a 
high propensity for anxiety, confirming our previous findings.16 These effects 
cannot be considered as a normal response to the diagnostic work up for breast 
disease, because not every woman responds similar to the threat of possibly 
having BC. The fact that women not prone to anxiety are affected more implies that 
being recalled for further diagnostic procedures after an ASM is a serious 
psychological problem, especially because the adverse effects persist at least one 
year after the diagnostic process showed by the lowered QoL.  
The present findings contribute to the ongoing screening controversy: are the 
advantages of the BC screening program still in balance with the disadvantages? 
Recent data has suggested that screening has little detectable impact on BC 
mortality.25 In addition, several publications have discussed the benefits and harms 
of the BC screening program.14,15,26-31 Currently the decision to participate in the 
BC screening program is based upon information in favor of screening. The risk for 
4
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controversy.14,15 The adverse psychological consequences after a false-positive 
screening mammogram are already described before.7-11,16 However, to our 
knowledge, a comparison between women with BBD referred after ASM or PL has 
not yet been performed. We hypothesized that women referred after ASM 
experience more adverse psychological effects compared with women referred 
with PL.  
As previously found, the negative effects in our study were strengthened by the 
personality characteristic trait anxiety, i.e. women with HTA scored unfavourably 
on state anxiety, depressive symptoms, and QoL, compared with women not prone 
to anxiety.6,10,12 Before diagnosis was known, all women scored higher on state 
anxiety and depressive symptoms compared with one month after diagnosis, when 
women were relieved that BC was not found. In addition, we have found that within 
women not prone to anxiety, those in the ASM group were more anxious before 
diagnosis was known and experienced more depressive symptoms at referral 
compared with all women with PL. In addition, those women reported impaired 
psychological QoL at referral and one year after diagnosis compared with PL. In 
chronically anxious women higher scores on depressive symptoms at referral were 
found compared with one month after diagnosis, regardless of being referred after 
an ASM or with a PL.   
Thus, the negative impact of a false-positive screening mammogram on anxiety, 
depressive symptoms and QoL is especially found in women who do not have a 
high propensity for anxiety, confirming our previous findings.16 These effects 
cannot be considered as a normal response to the diagnostic work up for breast 
disease, because not every woman responds similar to the threat of possibly 
having BC. The fact that women not prone to anxiety are affected more implies that 
being recalled for further diagnostic procedures after an ASM is a serious 
psychological problem, especially because the adverse effects persist at least one 
year after the diagnostic process showed by the lowered QoL.  
The present findings contribute to the ongoing screening controversy: are the 
advantages of the BC screening program still in balance with the disadvantages? 
Recent data has suggested that screening has little detectable impact on BC 
mortality.25 In addition, several publications have discussed the benefits and harms 
of the BC screening program.14,15,26-31 Currently the decision to participate in the 
BC screening program is based upon information in favor of screening. The risk for 
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possible adverse psychological consequences, overdiagnosis and overtreatment 
are not mentioned in the provided information.14,28-30,32,33  
 
Conclusions 
This study reveals that women recalled after an ASM experience higher state 
anxiety and depressive symptoms at referral with lowered QoL one year after 
diagnosis, compared with women with a PL, especially women not prone to 
anxiety. Therefore, we recommend that women should be informed properly 
concerning the benefits and risks of the BC screening program, in particular 
mentioning the adverse psychological consequences after a false-positive 
screening mammogram. In addition, at intake women should be offered a 
psychometric test to identify those who are at risk for impaired QoL. 
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are not mentioned in the provided information.14,28-30,32,33  
 
Conclusions 
This study reveals that women recalled after an ASM experience higher state 
anxiety and depressive symptoms at referral with lowered QoL one year after 
diagnosis, compared with women with a PL, especially women not prone to 
anxiety. Therefore, we recommend that women should be informed properly 
concerning the benefits and risks of the BC screening program, in particular 
mentioning the adverse psychological consequences after a false-positive 
screening mammogram. In addition, at intake women should be offered a 
psychometric test to identify those who are at risk for impaired QoL. 
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We analysed health care utilization (HCU) and its predictors in the first year after 
the diagnostic process for breast cancer (BC) or benign breast disease (BBD). The 
impact of trait anxiety on HCU was examined.  
 
Methods 
From June 2007 until October 2009 women referred with a palpable lump in the 
breast or an abnormality on a screening mammogram, were asked to participate. 
Questionnaires were completed before diagnosis was known and after one year. 
The questionnaires used assessed personality (STAI-Trait, NEO-FFI), depressive 
symptoms (CES-D), fatigue (FAS), and quality of life (WHOQOL-Bref). HCU was 
measured with self-report questionnaire.  
 
Results 
In total 591 women were analysed, 440 with BBD and 151 with BC. In women with 
BBD and high trait anxiety (HTA) increased HCU was found. In women with BC 
and HTA only more use of psychosocial care (PS) was found. HCU in BBD was 




The most important factors for higher HCU were HTA and lower QoL, especially in 
BBD. In women with BC increased PS use was seen in chronically anxious 
women. Therefore, it is important to identify these women using a psychometric 
test and to anticipate to their specific (mental) health care needs.   
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Nowadays, one in eight women in the western world will ultimately be diagnosed 
with breast cancer (BC).1,2,3 However, in our experience, the majority of women 
presenting at the surgical outpatient clinic with breast symptoms or referred after 
an abnormal screening mammogram, are diagnosed with benign breast disease 
(BBD).4 This large group of women is important to consider, because these women 
report increased levels of anxiety before and during the diagnostic process 
comparable with women with BC.5-7 These levels of anxiety diminish after the 
diagnostic process is completed, but a significant amount of women with the 
diagnosis BBD are not completely reassured.7,8   
A recent review revealed that trait anxiety was predictive for experienced levels of 
anxiety during the diagnostic process for suspected BC.9 In addition, previous 
studies have shown that trait anxiety is not only an important predictor for anxiety, 
but also for quality of life (QoL) in women with BBD or BC.4,7,10  
Trait anxiety refers to the tendency to respond to situations perceived as 
threatening with a rise in anxiety intensity.11 Women who are chronically anxious 
tend to perceive new situations, for example a possible diagnosis BC, as 
threatening and therefore experience higher levels of anxiety. These higher levels 
of anxiety and lowered QoL could be reason for an increase in health care 
utilization (HCU) in women with BBD or BC, especially in those who score high on 
trait anxiety (HTA). However, limited research concerning HCU in women with BBD 
or BC is performed. A few studies examined which factors may contribute to 
increased HCU for BC patients only, resulting in the following predictors: younger 
age, breast amputation, co-morbidity, older age, not having a partner, 
radiotherapy, cancer-related health problems, depression, and breast 
reconstruction.12-15  
We believe it is important to determine the patterns and the predictors of HCU in 
women with BBD or BD. With this knowledge about the medical and psychosocial 
needs of these women it will be possible to anticipate to those needs and 
eventually adjust the current follow-up protocol guidelines.  
We evaluated the HCU and the predictors for HCU in women with BBD or BC 
during the first year following the diagnosis. A comparison in HCU was done 
between women with BBD or BC. Contrary to most studies concerning personality 
and QoL, in this prospective, longitudinal study women completed the first set of 
questionnaires before any diagnostic procedures were carried out and thus before 
diagnosis was known. Firstly, we hypothesized that women with HTA would have 
increased HCU in the first year after diagnosis, in both the BBD and the BC group. 
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Secondly, based on previous research and experience we expected that HCU was 
predicted by QoL, fatigue and depressive symptoms.  
 
Patients and methods  
 
Participants 
The present study was performed in five teaching hospitals in the Netherlands. 
From June 2007 until October 2009 women referred with a palpable lump in the 
breast or an abnormality on a screening mammogram, were asked to participate in 
this study. The present study is part of a larger prospective, longitudinal study 
focusing on the impact of personality and QoL on morbidity, mortality and health 
care utilization in women with benign or malignant breast disease. At the time 
women gave written informed consent and completed the first set of 
questionnaires, the diagnosis was not yet known. If women were not able to 
complete Dutch questionnaires for linguistic or cognitive reasons, or if they had a 
medical history with BC or a psychiatric disease, they were excluded from the 
study. Women with advanced BC disease were excluded. The protocol of the study 
was approved by the local Medical Ethical Committee.  
 
Health Care Utilization 
HCU was divided in three major categories: visits to the general practitioner (GP), 
visits to the medical specialist (MD), and the use of psychosocial health care (PS), 
i.e. psychologist, welfare worker, self-help groups. After 12 months HCU was 
measured by self-report questions concerning visits and contacts with the GP, MD, 
and PS during the first year after diagnosis.  
 
Questionnaires 
Questionnaires were completed before any diagnostic procedures were carried out 
and thus before diagnosis was known. The questionnaires used assessed 
personality (STAI-Trait, NEO-FFI), depressive symptoms (CES-D), fatigue (FAS), 
and quality of life (WHOQOL-Bref). 
Trait and state anxiety were measured with the State and Trait Anxiety Inventory 
(STAI).11,16 Trait anxiety concerns differences in individuals in the disposition to 
respond to stressful situations with varying amounts of stress. State anxiety is a 
momentary emotional condition characterized by subjective feeling of 
apprehension and tension.11,16 The trait anxiety scores were dichotomized in high 
or not-high. In this study the short forms of both the STAI-Trait and the STAI-State 
were completed. These short versions of the STAI-State (6-items) and STAI-Trait 
(10-items) have good reliability and validity.17 
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The personality trait neuroticism was measured by the neuroticism part (12-items) 
of the Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI).18,19 
Neuroticism describes the predisposition to emotional instability, i.e. the tendency 
to experience no distressing emotions such as fear, guilt and frustration. The 
reliability and validity of this questionnaire are good.18 
The Center for Epidemiological Studies-Depression Scale (CES-D) measures the 
presence and degree of depressive symptoms. The short version with 16-items 
was used, which was found to be a valid assessment of depressive symptoms in 
cancer patients.20,21   
Fatigue was measured by the 10-items Fatigue Assessment Scale (FAS).22 The 
reliability and validity of the FAS appears to be good in women with breast 
problems.23 
The World Health Organization Quality of Life instrument, short form (WHOQOL-
Bref) was used to assess QoL.24 This questionnaire consists of four domains 
(Physical health, Psychological health, Social relationships and Environment) and 
two items concerning Overall QoL and general health. Higher scores indicate a 
better subjective QoL. Reliability and validity are reported to be good in women 
with breast problems.25  
 
Demographical and medical information 
Demographic data were obtained at baseline concerning age, marital status, 
having children, education level, and work status. Information on disease stage at 
diagnosis26, type of operation, and adjuvant therapy (chemotherapy, radiotherapy, 
hormone therapy) was retrieved from patients’ medical records. 
 
Statistical procedures 
For baseline measures, chi-square (discrete variables) and independent samples t-
tests (continuous variables) were used to compare drop-outs and non-drop-outs. 
To examine differences in visits to the GP, MD and PS (i) in the groups BBD and 
BC, and (ii) in patients with HTA or not-high score on trait anxiety (NHTA) in the 
BBD and BC group, chi-square tests (discrete variables) and independent samples 
t-tests (continuous variables) were used.  
Multivariate regression analyses were used to assess which factors were 
significant predictors of the number of contacts with the GP or MD and whether a 
patient used psychosocial health care in the first year following diagnosis. The 
independent variables included in the analyses were the following: demographics, 
disease stage, (adjuvant) therapy, personality, and baseline scores for state 
anxiety, depression, fatigue, and QoL domains. All analyses were performed with 
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During the study period 754 women were included, of whom 163 women did not 
complete all questionnaires after 12 months follow-up. Baseline demographics and 
personality were compared between drop-outs (N=163) and non-drop-outs 
(N=591): in the drop-out group more women were diagnosed with BBD, scored 
high on trait anxiety, and were less often referred by the national screening 
program.  
 
Table 1 Demographics, personality, and treatment characteristics of women with benign breast disease 
(BBD) and women with breast cancer (BC)  
 BBD N=440 BC N=151 P 
 
Age (years) * 49.9 (10.5) 59.1 (9.2) <0.001 
 
Partner  
















     Low (< 10 years) 
     Middle (11-14 years) 













Work status  







Screening referral ^  








     Scores on trait anxiety * 
     High trait anxiety 













Disease stage at diagnosis 
     Stage 0 
     Stage I 
     Stage IIa 
     Stage IIb 










Type of operation 
     Breast Conserving Treatment 
     Mastectomy 







     Received chemotherapy 
     Received radiotherapy 






Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.). Significant 
p-values are presented in bold. ^ Screening referral = women referred by the national breast cancer 
screening program.  
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In total 591 women were analysed, of whom 440 were diagnosed with BBD and 
151 with BC. Women with BBD and BC were compared concerning demographic 
variables, personality at baseline and HCU (Table 1). In the BBD group the HCU 
for the GP, MD, and PS was significantly lower in the first year after diagnosis 
compared with the BC group (Table 2).   
Subsequently, women were divided in four groups based on diagnosis (BBD or 
BC) and score on trait anxiety at baseline (HTA or NHTA). Women with BBD and 
HTA visited the GP more often than women with BBD and NHTA (p=0.003). The 
percentage of women with BBD visiting the MD was higher in women with HTA 
(p=0.043; Table 2). Concerning psychosocial care in the BBD group, women with 
HTA used this modality more frequently compared with women with NHTA 
(p<0.001). In women with BC and HTA more use of psychosocial care was found 
(p=0.002; Table 2). 
 
Table 2 Health care utilization in the first year after diagnosis divided in four groups based  
on diagnosis, benign breast disease (BBD) and breast cancer (BC), and score on trait anxiety (high or 
not-high) 































































118 (80)  














127 (85)  




















Values in parentheses are percentage unless indicated otherwise. * values are mean (s.d.). Significant 
p-values are presented in bold, comparing groups with high or not-high score on trait anxiety. BC values 
significant higher compared to BBD: p-values ^ <0.001, ° 0.028, > <0.001. GP = general practitioner; MD 
= medical doctor; PS = psychosocial health care. 
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Multiple regression analyses for the BBD and BC groups revealed that the most 
important predictors for HCU in the BBD group were several domains of QoL, and 
in the BC group the type of operation and adjuvant treatment. Multiple regression 
analyses for the four groups based on diagnosis (BBD or BC) and trait anxiety 
(HTA or NHTA) revealed several predictors (Table 3). 
In women in the BBD group with NHTA the predictors for increased HCU were 
lower scores on psychological, physical, general and environmental domains of 
QoL. In the BBD group women with HTA the predictors for increased HCU were 
not having work, lower score on general domain of QoL, and not having a partner 
(Table 3). In the BC group with NHTA the most important predictors for HCU were 
chemotherapy and lower score on social QoL, and in women with BC and HTA 
hormonal treatment, not having children, and educational level (Table 3).  
 
Table 3 Outcomes of the multiple regression analyses on significant predictors for health care utilization 
(HCU) in the first year after benign breast disease (BBD) and breast cancer (BC) and the high (HTA) or 
not-high score on trait anxiety (NHTA)  
HCU first year Group  Independent factor     R2    Beta          P 
 BBD     
GP  NHTA 
 
Environmental domain QoL 







 HTA Having work 0.111 -0.333 0.013 
MD  NHTA General domain QoL 0.051 -0.235 <0.001 
 HTA General domain QoL 0.086 -0.293 0.030 
PS  NHTA Psychological domain QoL 0.020 -0.140 0.011 
 HTA Having a partner 0.126 -0.355 0.007 
 BC     
GP NHTA 
 






























PS NHTA Having work 0.066 0.257 0.012 
GP = general practitioner; QoL= quality of life; MD = medical doctor; PS = psychosocial health care.  
R2 = percentage of variance in the scores of the dependent variable explained by the independent 
variable (1.00 = 100%); Beta: a negative Beta means that a higher score on the independent variable 
will result in a lower score of the dependent variable.  
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The aim of the present study was to analyse the HCU and the possible predictors 
for HCU in women with BBD or BC during the first year following the diagnosis. An 
increase in HCU was expected in women with HTA irrespective of the diagnosis.  
Overall, women with BC were visiting the GP and the MD more frequently 
compared with women with BBD. In previous studies these findings are confirmed 
in women after BC treatment, even fifteen years after diagnosis the HCU is found 
to be higher.12-14,27,28 This higher number of visits to the GP and MD is normal 
considering the BC (adjuvant) treatment during the first year. Subsequently, we 
found that chronically anxious women with BC used more psychosocial support 
during the first year after the diagnosis BC. This effect is not unexpected 
considering the higher levels of anxiety and lower QoL during the diagnostic 
process of suspected BC, especially in women with HTA.7 In women with BC even 
five years after the diagnosis a higher use of mental health care is still found, 
especially because of anxiety and sleep disorders.29 In women with BC no 
significant influence of HTA on GP and MD visits was seen. This effect is partly 
explained by the fact that all women with BC visit the GP and MD already very 
frequently as a part of their (adjuvant) treatment and follow-up protocol for BC. 
Apparently, even chronically anxious women experience this intensive standard 
follow-up as sufficient enough for comforting their fears and needs.  
However, in women with BBD, HTA had an evident impact on the use of GP, MD 
and PS. Trait anxiety can be defined as a relatively stable individual difference in 
anxiety proneness.11 Those chronically anxious women become even more 
anxious during the diagnostic process, and need more reassurance to confirm that 
the diagnosis is not BC. Apparently, this higher need for reassurance causes an 
increase in HCU. Previously, the higher need for reassurance was found especially 
in women with higher levels of anxiety and perceived stress.8  
In addition, important predictors for increased HCU in the multivariate regression 
analysis were lower scores on several QoL domains at baseline, irrespective of 
diagnosis. QoL as predictor for HCU in women was not found before, but in 
previous studies QoL was measured with SF-36 or SF-12 and QOL-CS.30,31 These 
questionnaires measure health status, which indicates whether there are 
limitations in physical possibilities, social activities, and state of mind, but reveals 
nothing about the feelings individuals have concerning their functioning. (General) 
QoL, however, also reflects to what extent a patient is bothered by limitations in 
daily life. Therefore, health status and QoL cannot be considered comparable or 
interchangeable for that matter.32 It is known that trait anxiety has a very profound 
impact on QoL, this influence is even more important than the diagnosis being 
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BBD or BC.4 The important influence of QoL on HCU is probably partly explained 
by this effect of trait anxiety on QoL. Apparently, chronically anxious women have 
an increased need for health care because the possibility of having BC is causing 
an extreme disturbance of their life with impaired QoL as a result.  
To our knowledge, this is the first study analysing trait anxiety and QoL scores as 
factors for predicting HCU in women with BBD or BC. In this study a true and valid 
baseline measurement, i.e. before the diagnosis was known, of both trait anxiety 
and QoL was done. This study is based on self-reported use of health care. 
Therefore, an underestimation of HCU is possible because of the effort of recalling 
all medical contacts in the previous 12 months. However, in both groups (BBD and 
BC) the same method was applied. In addition, more women with BBD and HTA 
were found in the drop-out group. If these women had not dropped out, we can 
assume that our results would have been even more convincing. 
 
Conclusions  
The most important factors for increased HCU were HTA and lower scores on 
QoL, especially in women with BBD. In women with BC a higher PS use was seen 
in chronically anxious women. Therefore, it is very important to identify women with 
a lower QoL score and/or HTA with a psychometric test, who may need extra 
(psychosocial) health care during and after the diagnostic process in case of a first 
event of breast disease. These women can then be offered a tailor-made follow-up 
protocol which will anticipate to their specific (mental) health care needs after the 
diagnosis BBD or BC. Through this individual approach women who need more 
support will be recognized and this will prevent that these women are unnecessary 
suffering without receiving extra (psychosocial) health care.  
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High trait anxiety (HTA) determines high state anxiety and depressive symptoms in 
women with breast cancer (BC) and benign breast disease (BBD). We examined 
whether this is caused by the combination of personality and diagnosis or solely by 
the personality characteristic HTA.  
 
Methods  
Women with breast disease (BD, N=357), diagnosed with BC (N=152) or BBD 
(N=205) and gallstone disease (GD, N=128) were included in a prospective 
longitudinal study. Questionnaires concerning trait anxiety (baseline), state anxiety, 
and depressive symptoms were completed pre-diagnosis (BC and BBD) or before 
the laparoscopic cholecystectomy and six months later. Multivariate linear 
regression analysis was performed to analyse the predictors for state anxiety and 
depressive symptoms at six months.   
 
Results  
Pre-diagnosis women with BD scored higher on state anxiety (p=0.001)  and 
depressive symptoms (p<0.001) compared with GD. At six months scores on 
depressive symptoms in BC remained higher than GD (p=0.005). Women with 
HTA scored unfavourably on state anxiety and depressive symptoms at all time 
points compared with women without HTA (p<0.001), especially women with BC. 
Regression analysis revealed that state anxiety and depressive symptoms at six 
months were predicted by depressive symptoms at baseline in women with BC.   
 
Conclusions  
The severity of diagnosis, i.e. BC, determines the impact on state anxiety and 
depressive symptoms in combination with HTA. Therefore, we recommend 
identifying those women with HTA or high state anxiety and/or depressive 
symptoms, and offer them a tailor-made follow-up protocol during and after the 
diagnostic process for BD. 
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Breast cancer (BC) is the most common type of cancer among women. One in 
eight women in the western world will be diagnosed with BC.1,2 However, the 
majority of women visiting a surgical outpatient clinic with breast problems are 
diagnosed with benign breast disease (BBD).3 Up to 50 per cent of these women 
with BBD, like women with BC, experience high levels of anxiety and distress 
during the diagnostic process.4-8 Before being diagnosed with BC, 28 per cent of 
women experience high levels of state anxiety in combination with depressive 
symptoms, which appears to be a major predictor of quality of life (QoL).9 The 
adverse psychological effects are strengthened by personality, i.e. women with a 
high score on trait anxiety (HTA) report more state anxiety, depressive symptoms, 
or distress during and after the diagnostic process for BC or BBD.5,6,8,10 Trait 
anxiety is defined as a relatively stable individual difference in anxiety proneness.11  
Thus, high state anxiety and depressive symptoms are important problems in 
women undergoing the diagnostic process for breast disease (BD = BC or BBD), 
especially in women with HTA. Therefore, we believe that a tailor-made follow-up 
protocol is required to prevent these adverse psychological consequences. 
However, before implementing such a protocol we need to know whether high 
state anxiety and depressive symptoms are caused by (the threat of) having BC or 
solely by the personality characteristic HTA. In other words, whether women with 
HTA experience high levels of state anxiety and depressive symptoms, irrespective 
of the diagnosis they are facing.  
Therefore, in the present study we compared women confronted with a possible 
life threatening disease (i.e. BC) and women with a non-life threatening disease, 
i.e. gallstone disease undergoing a laparoscopic cholecystectomy (GD). We 
examined the predictive value of trait anxiety and diagnosis for state anxiety and 
depressive symptoms. The GD group was chosen because it was previously found 
that HTA has a negative impact on QoL and persisting biliary symptoms after the 
operation in this group.12,13 We hypothesized that the severity of diagnosis, i.e. the 
suspicion of a malignant disease, will also be an important predictor for state 
anxiety and depressive symptoms, in addition to the personality characteristic trait 
anxiety.  
In this prospective longitudinal study we assessed trait anxiety, state anxiety, and 
depressive symptoms in women with BD before diagnosis was known or before 
admission to the hospital for the laparoscopic cholecystectomy. State anxiety and 
depressive symptoms were assessed again six months later.  
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Patients and Methods  
 
Participants 
Women analysed for the present study were recruited for two different studies. In 
one study concerning the role of psychological factors on recovery after surgery, 
patients with GD awaiting an elective laparoscopic cholecystectomy in one 
teaching hospital in the Netherlands between March 2006 and January 2008 were 
asked to participate. Before admission for the cholecystectomy the first set of 
questionnaires was completed. Exclusion criteria were severe comorbidity (ASA III 
or more), complicated GD or liver disease, and previous upper abdominal surgery. 
In the other study concerning QoL in women with early stage BC or BBD, between 
September 2002 and June 2007 women who were referred to three teaching 
hospitals with an abnormality on a screening mammogram or with a palpable lump 
in the breast were invited to participate. Women with recurrent BD were excluded 
from this study. At baseline women completed the first set of questionnaires before 
any diagnostic procedures were carried out and, thus, before the diagnosis was 
known. For both studies women with an inability to read and write in Dutch, or 
(previous) psychiatric illness were excluded. The Medical Ethical Board of the 
primary research hospital gave approval of both study protocols. All participants 
gave written informed consent. 
 
Questionnaires 
Questionnaires were completed at baseline and at six months. The questionnaires 
assessed anxiety as personality characteristic at baseline (STAI-Trait), and 
experienced momentary anxiety (STAI-State) and depressive symptoms (CES-D) 
at baseline and at six months.  
The Dutch version of the Spielberger State and Trait Anxiety Inventory (STAI) 
measures trait and state anxiety.11,14 Trait anxiety concerns differences in 
individuals in the disposition to respond to stressful situations with varying amounts 
of stress. State anxiety is a momentary emotional condition characterized by 
subjective feeling of apprehension and tension. It is a widely used questionnaire 
with good reliability and validity.11,14 High state anxiety was defined as a score 
greater than 38, and HTA with a score greater than 41.14 
The Centre for Epidemiological Studies-Depression Scale (CES-D) was used to 
assess depressive symptoms. It measures both the presence and the degree of 
depressive symptoms. The psychometric properties are good.15,16 In this study the 
16-items version was used and a high score on depressive symptoms was defined 
as a score greater than 12. 
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At baseline, women were also asked to complete a questionnaire concerning 
demographic characteristics as age, paid work, marital status, and education level. 
The medical data concerning patient, diagnostic and treatment characteristics were 
obtained from the medical records.  
 
Statistical procedures 
Women who did not complete all questionnaires at six months were considered as 
drop-outs and excluded from further analysis. For examining differences between 
the drop-out and non-drop-out groups and between the three groups based on 
diagnosis (GD, BBD and BC) with regard to baseline characteristics, chi-square 
tests (discrete variables) and one-way ANOVA (continuous variables) were used. 
Differences in demographic characteristics at baseline were used as co-variables 
in the subsequent analyses. At baseline before diagnosis was known, BC or BBD, 
women were analysed as a whole group with BD.  
A repeated measures general linear model (GLM) was used to examine scores on 
state anxiety and depressive symptoms across time (i) in the three groups GD, 
BBD and BC, and (ii) in patients with HTA or not-high score on trait anxiety (NHTA) 
in the GD, BBD and BC groups. When differences were found in the GLM between 
groups, one-way ANOVA was used to examine differences between groups at one 
particular measurement time. When differences were found in the GLM within one 
group concerning the scores at baseline compared with six months, paired t-tests 
were applied. Chi-square tests were used to analyse the changes of scores on 
state anxiety and depressive symptoms at six months compared with baseline 
(high or not-high).  
The predictors for state anxiety and depressive symptoms (dependent variables) at 
six months were found using the diagnosis and demographic characteristics (block 
1), scores on state anxiety and depressive symptoms at baseline (block 2), and 
trait anxiety (block 3) as independent variables in a multivariate linear regression 
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Patients and Methods  
 
Participants 
Women analysed for the present study were recruited for two different studies. In 
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patients with GD awaiting an elective laparoscopic cholecystectomy in one 
teaching hospital in the Netherlands between March 2006 and January 2008 were 
asked to participate. Before admission for the cholecystectomy the first set of 
questionnaires was completed. Exclusion criteria were severe comorbidity (ASA III 
or more), complicated GD or liver disease, and previous upper abdominal surgery. 
In the other study concerning QoL in women with early stage BC or BBD, between 
September 2002 and June 2007 women who were referred to three teaching 
hospitals with an abnormality on a screening mammogram or with a palpable lump 
in the breast were invited to participate. Women with recurrent BD were excluded 
from this study. At baseline women completed the first set of questionnaires before 
any diagnostic procedures were carried out and, thus, before the diagnosis was 
known. For both studies women with an inability to read and write in Dutch, or 
(previous) psychiatric illness were excluded. The Medical Ethical Board of the 
primary research hospital gave approval of both study protocols. All participants 
gave written informed consent. 
 
Questionnaires 
Questionnaires were completed at baseline and at six months. The questionnaires 
assessed anxiety as personality characteristic at baseline (STAI-Trait), and 
experienced momentary anxiety (STAI-State) and depressive symptoms (CES-D) 
at baseline and at six months.  
The Dutch version of the Spielberger State and Trait Anxiety Inventory (STAI) 
measures trait and state anxiety.11,14 Trait anxiety concerns differences in 
individuals in the disposition to respond to stressful situations with varying amounts 
of stress. State anxiety is a momentary emotional condition characterized by 
subjective feeling of apprehension and tension. It is a widely used questionnaire 
with good reliability and validity.11,14 High state anxiety was defined as a score 
greater than 38, and HTA with a score greater than 41.14 
The Centre for Epidemiological Studies-Depression Scale (CES-D) was used to 
assess depressive symptoms. It measures both the presence and the degree of 
depressive symptoms. The psychometric properties are good.15,16 In this study the 
16-items version was used and a high score on depressive symptoms was defined 
as a score greater than 12. 
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At baseline, women were also asked to complete a questionnaire concerning 
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state anxiety and depressive symptoms at six months compared with baseline 
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The predictors for state anxiety and depressive symptoms (dependent variables) at 
six months were found using the diagnosis and demographic characteristics (block 
1), scores on state anxiety and depressive symptoms at baseline (block 2), and 
trait anxiety (block 3) as independent variables in a multivariate linear regression 
analysis. A p-value < 0.05 was considered statistically significant. Statistical 
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women were diagnosed with BBD and 152 with BC. At baseline there were 
significant differences between groups concerning demographic characteristics, 
but no differences between groups were found concerning high scores on trait 
anxiety (Table 1). 
Before diagnosis was known (BC or BBD) mean state anxiety scores at baseline 
were significantly higher in de BD group compared with GD (p<0.001; Table 1). At 
six months the state anxiety scores were significantly diminished in all three groups 
compared with the baseline scores (p<0.001), and no differences were found 
between groups. Concerning depressive symptoms women with BD scored higher 
at baseline compared with GD (p<0.001). At six months depressive symptom 
scores were decreased in all three groups (p<0.001), but scores in BC were 
significantly higher compared with GD (p=0.005; Table 1). 
 
Table 1 Demographic, personality and psychological characteristics at baseline and at 6 months for 
four groups: gallstone disease (GD), benign breast disease (BBD), breast cancer (BC) and breast 
disease (BD, before diagnosis is known) 
 GD N=128 BBD N=205 BC N=152  P 
Demographics      
Age (years) * 46.2 (11.7) 53.8 (9.6) 57.2 (8.5)  ‡, ~ <0.001 
† 0.003 
Partner  111 (87) 171 (86) 126 (84)  NS  
 
Education > 14 yrs 35 (28) 40 (20) 25 (17)  ‡ 0.004 
~ 0.016  
Paid work 87 (69) 100 (49) 62 (41)  ‡, ~ <0.001  
      
Personality       
Trait anxiety score *  37.2 (9.6) 38.7 (11.0) 38.7 (11.1)  NS 
 
High trait anxiety 33 (26) 62 (30) 52 (34)  NS  
      
Psychological  
factors  
GD N=128 BBD N=205 BC N=152 BD N=357 P 
State anxiety  
baseline * 
38.4 (10.5) 39.9 (13.2) 47.1 (14.0) 43.0 (14.0) ‡, † <0.001  
^ 0.001 
State anxiety  
6 months * 
34.9 (12.0) ° 34.3 (11.8) ° 35.4 (11.7) °  NS 
      
Depressive symptoms 
baseline * 
7.5 (7.0) 10.9 (9.1) 10.1 (7.5) 10.6 (7.6) ‡ 0.024 
~, ^ <0.001 
Depressive symptoms 
6 months * 
5.1 (7.0) ° 7.0 (7.7) ° 7.9 (7.5) °  ‡ 0.005 
Values in parentheses are percentages unless indicated otherwise; * values are mean (s.d.). ‡ = GD 
compared with BC, ~ = GD compared with BBD, † = BBD compared with BC, ^ = BD compared with 
GD. NS = not significant. ° = difference between baseline and six months is significant. 
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In the whole group a high score on anxiety at baseline was found in 164 women 
(34 per cent), of whom 61 women scored also high at six months (per diagnosis 24 
in BC, 26 in BBD and 11 in GD). Concerning depressive symptoms at baseline a 
high score was found in 152 women (31 per cent), and at six months 65 women 
remained scoring high (per diagnosis 27 in BC, 31 in BBD and 7 in GD).   
Subsequently, women were divided in four groups (BD with HTA, BD with NHTA, 
GD with HTA, GD with NHTA) and in six groups when BD was split into BC and 
BBD based on diagnosis combined with the score on trait anxiety (HTA or NHTA). 
For each diagnosis group, women with HTA scored higher on state anxiety and 
depressive symptoms compared with women with NHTA at all time points 
(p<0.001; Table 2). 
 
Table 2 Mean scores on state anxiety and depressive symptoms at baseline and at six months  
for the groups divided per diagnosis: gallstone disease (GD), breast disease (BD), benign breast 
disease (BBD) and breast cancer (BC), and score on trait anxiety (high or not-high)  
 GD BD BBD BC P 
 










State anxiety  
baseline  
46.5 (10.4) 55.0 (11.7) 52.5 (12.4) 58.0 (10.2) ‡, ^ <0.001 
~ 0.040 † 0.030 
State anxiety  
6 months  
46.2 (15.9)  44.9 (12.5) ° 44.7 (10.3) ° NS 
      
Depressive symptoms 
baseline  
13.0 (7.8) 16.7 (8.8) 18.0 (9.6) 15.1 (7.7) ^ 0.030  
~ 0.020 
Depressive symptoms  
6 months  
11.1 (9.7)  12.9 (9.8) ° 13.4 (7.8) NS 
 










State anxiety  
baseline  
35.6 (9.1) 37.4 (11.1) 34.5 (9.2) 41.5 (12.3) ‡, † <0.001 
State anxiety  
6 months  
31.0 (7.1) °  29.7 (8.0) ° 30.6 (9.3) ° NS 
      
Depressive symptoms 
baseline  
5.6 (5.6) 7.7 (6.5) 7.9 (7.0) 7.5 (5.9) ^ 0.006 
~ 0.021 
Depressive symptoms  
6 months  
3.0 (4.3) °  4.6 (5.0) ° 5.0 (5.4) ° ‡ 0.018 
Values are mean (s.d.). ‡ = GD compared with BC, ~ = GD compared with BBD, † = BBD compared 
with BC, ^ = BD compared with GD. NS = not significant. ° = difference between baseline and six 
months is significant. * All values in women with high trait anxiety compared with not-high trait anxiety 
are significant different, p < 0.001. 
 
High trait anxiety 
At baseline before women were diagnosed with BC or BBD, scores on state 
anxiety (p<0.001) and depressive symptoms (p=0.030) were higher compared with 
GD (Table 2). At six months state anxiety was diminished in the BC and BBD 
group (p<0.001), without any change in the GD group, and no differences between 
the three groups were found. Concerning depressive symptoms, only in women 
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with BBD this score significantly diminished at six months (p=0.001; Table 2; Fig. 
2). A high score at baseline and at six months on state anxiety per diagnosis was 
found in 20 women with BC, 24 in BBD and 11 in GD. Concerning depressive 
symptoms these numbers were 20 in BC, 26 in BBD and 5 in GD respectively 
(p=0.048).   
 
Not-high trait anxiety 
At baseline women in the BD group scored similar on state anxiety compared with 
GD (Table 2; Fig. 1). Concerning depressive symptoms, at baseline higher scores 
in the BD group were found compared with GD (p=0.006). At six months scores on 
state anxiety were decreased in all groups and no differences between groups 
were found. At six months the scores on depressive symptoms in all groups 
significantly diminished (p<0.001), and BC scored higher than GD (p=0.018).  
 
Predictors of state anxiety and depressive symptoms at six months 
The most important predictor for state anxiety at six months in the BC group was 
depressive symptoms at baseline (28 per cent of variance). For GD and BBD state 
anxiety at baseline was the most important predictor for state anxiety at six months 
(30 per cent and 26 per cent of the variance respectively). For depressive 
symptoms at six months in all three groups the most important predictor was 
depressive symptoms at baseline (Table 3). Trait anxiety was found to be 
predictive for state anxiety and depressive symptoms in addition to the baseline 
scores of these psychological factors themselves.  
 
Table 3 Regression analyses for state anxiety and depressive symptoms at six months per diagnosis: 
gallstone disease (GD), benign breast disease (BBD) and breast cancer (BC) 
Dependent factor Diagnosis Independent factor R2 Beta P 
























































R2 = the proportion of variance in the scores of the dependent variable explained by the independent 
variable (1.00 = 100%); a negative Beta means that a higher score for the independent variable will 
result in a lower score for the dependent variable.   
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Figure 1 and 2 State anxiety (general mean scores) and depressive symptoms at baseline and at six 
months per diagnosis and per score on trait anxiety 
NHTA = not-high trait anxiety, GD = gallstone disease, BBD = benign breast disease, BC = breast 
cancer, HTA = high trait anxiety 
   
  Fig. 1 
 
  Fig. 2 
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HTA determines high state anxiety and depressive symptoms in women with BC. 
We hypothesized that the possibility of having a life threatening disease, i.e. BC, 
will also be an important predictor for state anxiety and depressive symptoms, in 
addition to the personality characteristic trait anxiety. 
As expected, the effects on state anxiety and depressive symptoms were 
heightened in women with HTA.5,6,8,10 However, at baseline women in the HTA 
group with BD experienced more momentary anxiety than women with GD. 
Apparently in women with HTA the possible diagnosis BC is much more 
threatening than undergoing a laparoscopic cholecystectomy, which did not cause 
any changes in state anxiety in GD. Differences in state anxiety at baseline were 
also found in women in the NHTA group, women with BC experienced higher 
levels of state anxiety compared with GD or BBD. These findings confirm our 
previous study in which the fear of being diagnosed with BC, i.e. a false-positive 
screening mammogram, causes momentary anxiety not only in chronically anxious 
women but also in women who are not prone to anxiety.17 Even though women 
with BD are all similarly referred to the outpatient surgical clinic with a palpable 
lump or after an abnormal screening mammogram, women diagnosed with BC 
were more anxious than women who appeared to have BBD, irrespective of HTA 
or NHTA. Apparently, these women eventually diagnosed with BC have an 
unconsciously awareness of possibly having BC, which explains the significant 
differences found between BBD and BC prior to diagnosis. These findings confirm 
our hypothesis that the threat of having BC has a serious impact on state anxiety, 
in addition to HTA.  
Concerning depressive symptoms, women with BD scored higher compared with 
GD at baseline, which is found in women with HTA or NHTA. In contrast with state 
anxiety scores, depressive symptoms remained higher at six months in BC 
compared with GD in women with NHTA. In addition, in the HTA group more 
women with BC scored high on depressive symptoms at baseline and at six 
months compared with GD. Apparently, the threat of possibly having BC causes 
only severe momentary anxiety before diagnosis is known, but causes long-term 
effects such as depressive symptoms in women diagnosed with BC. Probably 
higher scores on depressive symptoms are not only caused by the BC diagnosis 
itself, but are also a result of the BC treatment.  
The regression analysis revealed that state anxiety and depressive symptoms at 
six months is predicted by depressive symptoms at baseline in the BC group, up to 
28 per cent of variance. In contrast, trait anxiety is also found to be a predictor but 
only up to a maximum of 11 per cent of variance. Thus, women diagnosed with BC 
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and a high score on depressive symptoms at baseline are at risk for ongoing 
anxiety and depressive symptoms six months after the surgery, which is 
strengthened in women with HTA.  
Our present findings support our hypothesis that chronically anxious women do not 
always become more anxious and that the severity of diagnosis, i.e. benign or 
malignant breast disease versus GD, determines the impact on state anxiety and 
depressive symptoms in combination with HTA. These results are important to 
consider, because previously it was found that women with high scores on state 
anxiety and depressive symptoms prior to BC diagnosis, are at risk for impaired 
QoL up to two years after surgery.9 In addition, both impaired QoL and HTA were 
found to be predictors for increased health care consumption up to one year after 
the diagnostic process in women with BBD.18 In women diagnosed with BC and 
HTA increased use of psychosocial care was found one year after surgery.18  
 
Conclusions  
This study reveals that women who are confronted with the possibility of having 
BC, experience higher state anxiety and depressive symptoms prior to diagnosis 
than women with GD, these effects are heightened in women with HTA. Therefore, 
we recommend offering women with BD a psychometric test to identify those 
women with HTA or a high score on state anxiety and/or depressive symptoms 
prior to the diagnosis BC or BBD. These women should be offered a tailor-made 
support protocol during and after the diagnostic process for BD. With this individual 
approach, which will anticipate on specific (mental) health care needs, impaired 
QoL or increased health care utilization may be prevented.  
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support protocol during and after the diagnostic process for BD. With this individual 
approach, which will anticipate on specific (mental) health care needs, impaired 
QoL or increased health care utilization may be prevented.  
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High trait anxiety (HTA) causes impairment in quality of life (QoL) and fatigue in 
women with breast cancer (BC) and benign breast disease (BBD). We examined 
whether the lowered QoL was caused solely by the personality characteristic HTA 
or the combination of personality and diagnosis.  
 
Methods 
Women with BC (N=152), BBD (N=205), and gallstone disease (GD, N=128) were 
included in a prospective, longitudinal study. Pre-diagnosis (BC and BBD) or 
before the laparoscopic cholecystectomy (GD) as well as six months later, 
questionnaires concerning trait anxiety (baseline), fatigue, and QoL were 
completed. Multivariate linear regression analysis was performed to analyse the 
predictors for QoL at six months.  
 
Results  
At six months QoL scores were significantly increased in the GD group, especially 
in women with not-HTA (NHTA), whereas fatigue remained stable across time, in 
both HTA and NHTA groups. At six months in women with NHTA and BBD the 
scores for fatigue and physical QoL had significantly improved, and in women with 
NHTA and BC a decrease in physical QoL and an increase in fatigue at six months 
were found. Women with HTA scored unfavourably on fatigue and QoL compared 
with women with NHTA at both time points. Regression analysis revealed that HTA 
and the change of fatigue score across time were the most important factors of 
influence concerning QoL.  
 
Conclusions  
The course of QoL and fatigue during follow-up were significantly different for each 
diagnosis. Particularly HTA had a negative impact on patients’ QoL and fatigue. In 
addition, for some scales diagnosis also played a role. Especially the combination 
HTA and the diagnosis BC caused a negative impact on QoL and fatigue. We 
recommend identifying women with BC and HTA, who are at risk for diminished 
QoL, and offer them a tailor-made follow-up protocol.  
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Breast cancer (BC) is the most common type of cancer among women. One in 
eight women in the western world will be diagnosed with BC.1,2 Due to 
improvements in adjuvant treatment and early detection, BC is no longer a life 
threatening disease for many women.3 As a result, long-term consequences of BC 
diagnosis and treatment, such as impairment in quality of life (QoL), are becoming 
more important. Diminished QoL has been found in women many years after BC 
treatment.4,5 In contrast, a systematic review has found a good overall QoL in long-
term BC survivors, but with BC specific problems.6 Factors determining QoL are 
becoming a subject of great interest in order to prevent diminished QoL. QoL is 
predicted by factors such as adjuvant therapy, psychological distress, pain, arm 
morbidity, depressive symptoms, postmenopausal symptoms and fatigue.7-9 
Fatigue is a common problem during and after BC treatment, in up to 50 per cent 
of the women.10-12 In addition, high trait anxiety (HTA) appears to influence QoL 
negatively13-15, and determines the risk for developing fatigue in women with BC.16 
Trait anxiety is defined as a relatively stable individual difference in anxiety 
proneness, i.e. trait anxiety is a personality factor.17 
Thus, impairment in QoL and fatigue are important problems in women with BC. In 
addition, fatigue itself is an important predictor for QoL.7,8 Fatigue and QoL are 
both negatively influenced by the personality characteristic trait anxiety. Before 
implementing a tailor-made follow-up protocol for women with HTA to prevent 
adverse psychological problems after BC diagnosis and treatment, it is important to 
evaluate whether the diminished QoL is caused by (the threat of) having BC or 
solely by the personality characteristic HTA. In other words, whether women with 
HTA experience lowered QoL, irrespective of having a malignant or benign 
diagnosis.  
To our knowledge, this is the first study comparing women with a possible life 
threatening disease (i.e. diagnosis BC and benign breast disease (BBD) known 
after baseline) and women with a non-life threatening disease, i.e. gallstone 
disease, undergoing a laparoscopic cholecystectomy (GD), with respect to QoL. 
The GD group was chosen because it was previously found that trait anxiety and 
fatigue have a negative impact on the QoL in this group.18 We examined the 
predictive value of trait anxiety on the course of QoL and fatigue across time for 
the different diagnoses. We hypothesized that in addition to the personality 
characteristic trait anxiety the threat of a high impact disease (i.e. BC) will also be 
an important predictor of QoL. In addition, we analysed the impact of the change of 
fatigue across time on QoL, because fatigue is a serious problem in women with 
7
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BC10-12 and is an important predictor for QoL.7,8 In this prospective longitudinal 
study we assessed trait anxiety, fatigue, and QoL pre-diagnosis in women with 
breast disease or before admission to the hospital for the elective laparoscopic 
cholecystectomy. Fatigue and QoL were assessed again six months later.  
 
Patients and Methods  
 
Participants 
Women analysed for the present study were recruited for two different studies. In 
one study concerning the role of psychological factors on recovery after surgery, 
patients were recruited in one teaching hospital in the Netherlands between March 
2006 and January 2008. Patients with GD awaiting an elective laparoscopic 
cholecystectomy were asked to participate. The first set of questionnaires was 
completed before admission for the cholecystectomy. Exclusion criteria were 
severe comorbidity (ASA III or more), complicated GD or liver disease, and 
previous upper abdominal surgery. In the other study concerning QoL in women 
with early stage BC or BBD, women who were referred with an abnormality on a 
screening mammogram or with a palpable lump in the breast to three teaching 
hospitals were invited to participate between September 2002 and June 2007. 
Women with recurrent (benign) breast disease were excluded from this study. At 
baseline, before any diagnostic procedures were carried out and, thus, before the 
diagnosis was known, women completed the first set of questionnaires. For both 
studies, women with insufficient knowledge of the Dutch language or a (history of) 
psychiatric disease were excluded. The Medical Ethical Committee of the primary 
research hospital gave approval of both study protocols. All participants gave 
written informed consent. 
 
Questionnaires 
The questionnaires assessing trait anxiety (STAI-Trait), fatigue (FAS) and QoL 
(WHOQOL-Bref) were completed at baseline, i.e. before diagnosis was known in 
the breast disease group and before hospital admission in the GD group. The 
fatigue and QoL questionnaires were also completed at six months follow-up.  
The Dutch version of the Spielberger State and Trait Anxiety Inventory (STAI) 
measures trait and state anxiety.17,19 For this study only trait anxiety was used. It is 
a widely used questionnaire with good reliability and validity.17,19 HTA was defined 
as a score greater than 41.19  
Fatigue was measured by the 10-items Fatigue Assessment Scale (FAS).20 The 
reliability and validity of the FAS appear to be good in women with breast problems 
and the general population.20,21 The cut-off score was 22 or higher.  
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The World Health Organization Quality of Life assessment instrument-Bref is a 
generic, cross-culturally developed comprehensive measure of QoL.22 It is the 
short version of the WHOQOL-100 questionnaire.23,24 The WHOQOL-Bref 
measures QoL in four domains (Physical health, Psychological health, Social 
relationships and Environment) and the facet Overall QoL and general health. The 
psychometric properties of the WHOQOL-Bref are good, also in women with 
(benign) breast disease.22,25  
At baseline, women were also asked to complete a questionnaire concerning 
demographic characteristics (age, paid work, marital status, and education level). 
The medical data concerning patient, diagnostic and treatment characteristics were 
obtained from the medical records.  
 
Statistical procedures 
Women who did not complete all questionnaires at six months were excluded from 
further analysis and considered as drop-outs. For examining differences between 
the drop-out and non-drop-out groups and between GD, BBD and BC, with regard 
to personality trait anxiety and demographic characteristics at baseline, chi-square 
tests (discrete variables) and one-way ANOVA (continuous variables) were used. 
Differences in demographic characteristics at baseline were used as co-variables 
in the subsequent analyses.  
A repeated measures general linear model (GLM) was used to examine scores on 
fatigue and QoL across time (i) in the three groups GD, BBD and BC, and (ii) in 
patients with HTA or not-high score on trait anxiety (NHTA) in the GD, BBD and 
BC groups. When differences were found in the GLM between groups, one-way 
ANOVA was used to examine differences between groups at one particular 
measurement time. When differences were found in the GLM within one group 
concerning the scores at baseline compared with six months, paired t-tests were 
applied.  
The predictors of QoL at six months after diagnosis (dependent variable) were 
found using the diagnosis and demographic characteristics (block 1), 
chemotherapy and/or radiotherapy in women with BC and the change of scores on 
fatigue across time (block 2), and trait anxiety (block 3) as independent variables in 
a multivariate linear regression analysis. A p-value < 0.05 was considered 
statistically significant. All analyses were performed with the Statistical Package for 
Social Sciences® (SPSS version 18.0). 
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During the study period 740 women were included, of whom 255 women did not 
complete all questionnaires at six months and were excluded from further analysis. 
The demographic and personality characteristics at baseline were compared 
between drop-outs and non-drop-outs. In the drop-out group women were older 
(p=0.040) and breast disease was diagnosed more often (p<0.001). Concerning 
HTA no differences were found.   
In total 485 women were included in the analysis, of whom 128 women with GD, 
205 with BBD and 152 with BC. At baseline, significant differences between groups 
were observed concerning demographics. Women in the BC and BBD groups were 
older (p<0.001), had a lower level of education (p=0.004, p=0.016) and less 
women had paid work (p<0.001) compared with the GD group. Women with BC 
were older than women with BBD (p<0.001). High scores on trait anxiety were 
comparable between groups (Table 1). The percentage of women with HTA or high 
fatigue at baseline was not significantly different between groups.  
In Table 2 mean QoL and fatigue scores are shown for the three patient groups at 
both time points. Subsequently, women were divided in six groups based on 
diagnosis (GD, BBD and BC) and the score on trait anxiety at baseline (HTA or 
NHTA). For each diagnosis women with HTA scored higher on fatigue and lower 
on QoL at both time points compared with women with NHTA (p<0.001; Fig. 1a-d, 
Fig. 2). 
 
Table 1 Demographic and personality characteristics at baseline for three groups: gallstone disease 
(GD), benign breast disease (BBD) and breast cancer (BC) 
 GD N=128 BBD N=205 BC N=152 P 
Demographics      
Age (years) * 46.2 (11.7) 53.8 (9.6) 57.2 (8.5) ‡, ~, † <0.001 
Partner 111 (87) 171 (86) 126 (84) NS 
Education > 14 yrs 35 (28) 40 (20) 25 (17) ‡ 0.004, ~ 0.016 
Paid work 87 (69) 100 (49) 62 (41) ‡, ~ <0.001 
     
Personality      
Trait anxiety score * 37.2 (9.6) 38.7 (11.0) 38.7 (11.1) NS 
Women with HTA 33 (26) 62 (30) 52 (34) NS 
Values in parentheses are percentages unless indicated otherwise; * values are mean (s.d.). NS = not 
significant. ‡ = GD versus BC, ~ = GD versus BBD, † = BBD versus BC, HTA = high score on trait 
anxiety. 
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Table 2 General and three domains of quality of life (QoL) and fatigue at baseline and at 6 months for 
three groups: gallstone disease (GD), benign breast disease (BBD) and breast cancer (BC) 
 GD N=128 BBD N=205 BC N=152  P 
QoL Baseline 6 months Baseline 6 months Baseline 6 months 
 
 
  General  7.0 (1.6) 7.7 (1.7) 7.5 (1.5) 7.7 (1.4) 7.6 (1.4) 7.6 (1.4) ‡ <0.001 
~ 0.003 
  Physical  13.7 (2.8) 15.7 (3.6) ° 15.1 (2.6) 15.5 (2.7) ° 15.5 (2.4) 14.9 (2.7) ° ‡ <0.001 
~ <0.001 
  Psychological  14.3 (2.6) 15.1 (2.9) 14.5 (2.1) 14.6 (2.2) 14.9 (2.2) 14.7 (2.4) 
 
 
  Social  15.9 (2.6) 15.4 (2.8) 15.9 (2.6) 15.7 (2.7) 16.6 (2.3) 15.9 (2.6) ‡ 0.030  
† 0.013 
Fatigue  21.0 (7.0) 21.2 (7.2) 21.3 (7.4) 20.0 (7.7) ° 19.8 (7.3) 21.7 (7.7) ° 
 
 
Values are mean (s.d.). ° = significant different between baseline and six months. Significant 
differences at baseline between diagnosis groups: ‡ = GD versus BC, ~ = GD versus BBD, † = BBD 
versus BC.  
 
High trait anxiety 
At six months in GD and BC the social QoL decreased (p=0.040 and p=0.001 
respectively; Fig. 1d) compared with scores at baseline. In BBD, scores on QoL did 
not change across time. At baseline women with GD scored lower on all domains 
of QoL compared with BC, except for general QoL (Fig. 1a-d). Women with BBD 
scored higher on physical (p=0.036) and psychological QoL (p=0.001) than women 
with GD, and scores on social QoL were lower in BBD than in BC (p=0.001). At six 
months scores on psychological QoL were lower in the GD group compared with 
BBD (p=0.029) and BC (p=0.047). No differences or changes in the three 
diagnosis groups were found for fatigue scores at both time points (Fig. 2).   
 
Not-high trait anxiety 
During follow-up the scores in the GD group significantly increased for physical, 
psychological and general QoL (p<0.001; Fig. 1a-c). At six months the scores on 
physical QoL increased in the BBD group (p=0.011) and decreased in the BC 
group (p=0.004) compared with baseline. Women with GD scored lower on general 
and physical QoL at baseline compared with BC. At baseline women with BBD 
scored higher on physical and general QoL than GD, and no differences were 
found between BBD and BC. At six months scores on psychological QoL were 
lower in the BBD group compared with GD (p=0.001). At six months an increase in 
fatigue scores was found in BC (p<0.001) and a decrease in the BBD group 
(p=0.012), without changes in the GD group. At baseline a higher score on fatigue 
was found in the BBD group compared with BC (p=0.010), and at six months no 
differences between groups were found (Fig. 2). 
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During the study period 740 women were included, of whom 255 women did not 
complete all questionnaires at six months and were excluded from further analysis. 
The demographic and personality characteristics at baseline were compared 
between drop-outs and non-drop-outs. In the drop-out group women were older 
(p=0.040) and breast disease was diagnosed more often (p<0.001). Concerning 
HTA no differences were found.   
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205 with BBD and 152 with BC. At baseline, significant differences between groups 
were observed concerning demographics. Women in the BC and BBD groups were 
older (p<0.001), had a lower level of education (p=0.004, p=0.016) and less 
women had paid work (p<0.001) compared with the GD group. Women with BC 
were older than women with BBD (p<0.001). High scores on trait anxiety were 
comparable between groups (Table 1). The percentage of women with HTA or high 
fatigue at baseline was not significantly different between groups.  
In Table 2 mean QoL and fatigue scores are shown for the three patient groups at 
both time points. Subsequently, women were divided in six groups based on 
diagnosis (GD, BBD and BC) and the score on trait anxiety at baseline (HTA or 
NHTA). For each diagnosis women with HTA scored higher on fatigue and lower 
on QoL at both time points compared with women with NHTA (p<0.001; Fig. 1a-d, 
Fig. 2). 
 
Table 1 Demographic and personality characteristics at baseline for three groups: gallstone disease 
(GD), benign breast disease (BBD) and breast cancer (BC) 
 GD N=128 BBD N=205 BC N=152 P 
Demographics      
Age (years) * 46.2 (11.7) 53.8 (9.6) 57.2 (8.5) ‡, ~, † <0.001 
Partner 111 (87) 171 (86) 126 (84) NS 
Education > 14 yrs 35 (28) 40 (20) 25 (17) ‡ 0.004, ~ 0.016 
Paid work 87 (69) 100 (49) 62 (41) ‡, ~ <0.001 
     
Personality      
Trait anxiety score * 37.2 (9.6) 38.7 (11.0) 38.7 (11.1) NS 
Women with HTA 33 (26) 62 (30) 52 (34) NS 
Values in parentheses are percentages unless indicated otherwise; * values are mean (s.d.). NS = not 
significant. ‡ = GD versus BC, ~ = GD versus BBD, † = BBD versus BC, HTA = high score on trait 
anxiety. 
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Figures 1 and 2 Quality of life (QoL) and fatigue at baseline and at six months for each diagnosis and 
score on trait anxiety 
NHTA = not-high trait anxiety, GD = gallstone disease, BBD = benign breast disease, BC = breast 
cancer, HTA = high trait anxiety 
 
  Fig. 1a 
 
 
  Fig. 1b  
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Predictors of quality of life at six months 
Regression analysis for the whole group and per diagnosis revealed that HTA and 
the change of scores on fatigue across time were the most important factors of 
influence concerning QoL at six months (Table 3). HTA was found to be the most 
important predictor for QoL in all three groups, up to 20 per cent in BBD and 28 per 
cent in BC, and 44 per cent in the GD group. Up to 10 per cent of variance in the 
scores in the BC group was explained by change of scores on fatigue across time, 
in the GD and BBD groups, for 7 per cent and 13 per cent respectively.   
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Table 3 Regression analyses for general and three domains of quality of life (QoL) at six months for 
each diagnosis 
 Dependent factor Independent factor R2 Beta P 




























 Social QoL Trait anxiety 0.217 -0.466 <0.001 
























































 Social QoL Trait anxiety 0.168 -0.410 <0.001 
GD = gallstone disease, BBD = benign breast disease, BC = breast cancer. R2 = percentage of variance 
in the scores of the dependent variable explained by the independent variable (1.00 = 100%); Beta: a 
negative Beta means that a higher score on the independent variable will result in a lower score of the 




HTA causes impairment in QoL in women with BC and BBD.13-15 However, whether 
these effects are caused by (the threat of) having BC or solely by the personality 
characteristic HTA has not been examined before. Therefore, the aim of this 
prospective longitudinal study was to analyse the impact of diagnosis, i.e. 
malignant or benign disease, on QoL. We hypothesized that in addition to the 
personality characteristic trait anxiety the threat of a high impact disease (i.e. BC) 
is also an important predictor of QoL.  
At baseline women with GD scored lower on several domains of QoL compared 
with BC, regardless of HTA. These lower scores can be explained by the daily 
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and/or long term complaints caused by the GD in contrast with women with 
(benign) breast disease without such restrictive physical problems. This is reflected 
by the fact that several scores on QoL significantly increased at six months in the 
GD group due to the relief of symptoms after the operation. This improvement of 
QoL was mainly found in women with NHTA. Perhaps it takes more than six 
months to overcome the impact of undergoing a laparoscopic cholecystectomy in 
women with HTA.  
In women with NHTA and BBD, the relief that BC was not found could explain why 
the scores for fatigue and physical QoL were significantly improved at six months. 
Only in women with NHTA these changes were found, probably it takes more than 
six months for women with HTA to overcome the threat of possibly having BC. In 
women with NHTA and BC the decrease in physical QoL and increase in fatigue at 
six months are not unexpected because of the possible side-effects of BC 
treatment. Thus, the change in QoL and fatigue during six months is significantly 
different for each diagnosis, in particular in women with NHTA. The changes can 
be explained by symptoms caused by either the disease or the medical treatment 
thereof.  
Women with HTA scored unfavourably on fatigue and QoL compared with women 
with NHTA at both time points, which is in accordance with previous studies.13-16 
Trait anxiety was found to be the most important factor of influence on QoL, in 
particular in women with GD up to 44 per cent, whereas in women with BC or BBD 
28 and 20 per cent respectively. Thus, in women confronted with a possible life 
threatening disease, i.e. BC or BBD, the impact of HTA is less important than in 
women with a non-life threatening disease, i.e. GD. Apparently, the diagnosis BC 
is much more threatening than GD, regardless of HTA. Thus, women with GD and 
HTA have a high risk for impairment in QoL, which is confirmed by the lower 
scores on psychological QoL at six months compared with BBD or BC.  
The other factor of influence on QoL at six months was the change of fatigue 
scores across time in all three diagnosis groups, within the BC group up to 10 per 
cent of variance. Only in women with BC we found that fatigue was significantly 
increased at six months compared with baseline. This implies that the diagnosis 
BC and probably even more its treatment determines, as a result of fatigue, the 
impact on QoL. The effects of BC diagnosis and its treatment could explain this 
ongoing fatigue.4,9-12 Our findings are in accordance with previous studies in which 
fatigue had the greatest impact on QoL in women with BC.7,8 Thus, these results 
strengthened our hypothesis that the severity of the diagnosis, i.e. benign or 
malignant disease, and the (medical) consequences of the diagnosis are predictors 
for QoL, in addition to the most important factor of influence the personality 
characteristic trait anxiety. 
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The present study reveals that the pattern and changes in QoL during follow-up 
were significantly different for each diagnosis. Especially HTA had a negative 
impact on patients’ QoL and fatigue. In addition, for some scales diagnosis also 
played a role. Particularly the combination HTA and the diagnosis BC caused a 
negative impact on QoL and fatigue. Therefore, we recommend identifying women 
with HTA who are at risk for adverse psychological effects with a psychometrically 
sound test. Those women with BC and HTA can then be offered a tailor-made 
support protocol. With this individual approach, which will anticipate on specific 
(mental) health care needs, impairment in QoL may be prevented.  
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Breast cancer screening program and its psychological consequences  
In the 1960s the breast cancer (BC) screening program has been introduced to 
achieve earlier detection with the potential to reduce BC mortality. However, recent 
studies suggested that screening has little detectable impact on BC mortality.1-3 
The disadvantages of the BC screening program, such as overdiagnosis, 
overtreatment, and a false-positive screening mammogram (FP) may have 
substantial consequences for women attending the BC screening program.3,4 As a 
consequence, recent publications have been discussing the screening controversy 
by questioning whether the benefits still justify the harms of the BC screening 
program.1-10   
To contribute to this ongoing discussion, the aim of the first part of this thesis was 
to determine the impact of an abnormal screening mammogram (ASM) on 
women’s psychological distress (state anxiety, depressive symptoms) and quality 
of life (QoL). Only a few studies have examined the impact of an ASM on health 
status or health-related QoL. Health status or health-related QoL measure the 
impact of disease on functioning, whereas QoL also reflects to what extent a 
patient is bothered by these limitations in daily life.11 Therefore, we measured QoL 
with the WHOQOL questionnaire which asks about satisfaction and not merely 
functioning. Previous reviews have described serious psychological consequences 
after an FP.12-15 However, examining the impact of the personality characteristic 
trait anxiety on the psychological consequences after an FP has not been done 
before. Trait anxiety refers to relatively stable individual differences in anxiety 
proneness.16 Also, comparing women with regard to the timing of the ASM (first 
versus repeat), or comparing women with benign breast disease (BBD) referred 
after an ASM or referred with a palpable lump was not performed before.  
 
Chapter two describes the impact of an FP on state anxiety and QoL until one 
year after diagnosis. In addition, the diagnostic process after an ASM was 
investigated. Women with an FP (N=233) were compared with women diagnosed 
with BC (N=152) after an ASM. Prior to diagnosis, women with BC were more 
anxious than women with an FP and experienced a decline in QoL one month after 
surgery. In the group with a high score on trait anxiety (HTA), women with an FP 
scored as high on state anxiety as women diagnosed with BC. Women with an FP 
and HTA reported diminished QoL until one year after the diagnosis compared with 
women with FP and without HTA (NHTA). These scores were even lower 
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women with FP and without HTA (NHTA). These scores were even lower 
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procedures (including biopsies) were needed in the FP group to reach the final 
benign diagnosis. Only 28 per cent of the women in the FP group could be 
diagnosed as BBD with a repeat mammogram. During the first year after 
screening, 55 per cent of the FP group returned to the outpatient clinic, some 
women up to eight times. Thus, women with HTA experienced high levels of 
momentary anxiety and impairment in QoL, regardless of being diagnosed as an 
FP or with BC. Being recalled for further diagnostic investigations after an ASM 
resulted in more histological biopsies and a high number of revisits to the 
outpatient clinic in the FP group.   
 
In chapter three we were especially interested in the timing of an ASM, i.e. first 
(N=186) or repeat (N=296) screening mammogram. We examined the effect of 
timing on psychological distress (state anxiety, depressive symptoms) and QoL. 
We hypothesized that being referred after a first ASM evokes more distress and 
impaired QoL compared with women referred after a repeat ASM. Those women 
with a repeat ASM have attended the program before without any problems and 
are, thus, “more experienced”. Therefore, we compared women referred for further 
additional investigation after a first ASM or after a repeat ASM. All women 
experienced high levels of anxiety and depressive symptoms before diagnosis was 
known compared with one month after the diagnosis. Prior to diagnosis, in the 
group of women with NHTA, higher state anxiety levels were found in the first ASM 
group than in the repeat ASM group. HTA was predictive for more state anxiety, 
depressive symptoms, and impaired QoL. Thus, negative psychological 
consequences after an FP are seen in all women. These effects are more 
heightened in women with HTA. Attending the screening program for the first time 
evoked more anxiety in women with NHTA.  
 
In chapter four we examined whether the previously found adverse psychological 
effects are found in all women diagnosed with BBD or in particular after an ASM. 
Women attending the BC screening program usually have no symptoms and, as a 
consequence, are not expecting an ASM. We hypothesized that these women are 
more alarmed by being recalled for further diagnostic procedures than women 
referred with a palpable lump in the breast. Women diagnosed with BBD after an 
ASM (N=363) were compared with women with a benign palpable lump in the 
breast (N=401). A similar score on state anxiety was found in both groups. A lower 
psychological QoL score at 12 months was seen in the ASM group. In women with 
NHTA, those in the ASM group were more anxious with more depressive 
symptoms prior to diagnosis compared with the women with a palpable lump in the 
breast. Within the NHTA group, women with an ASM reported lower psychological 
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QoL at baseline and at 12 months than women with a palpable lump. Women with 
HTA scored unfavourably on anxiety, depressive symptoms and QoL compared 
with women with NHTA. Thus, ASM evoked more anxiety and depressive 
symptoms prior to diagnosis with an ongoing impairment of QoL compared with 
women referred with a benign palpable lump in the breast, especially in women not 
prone to anxiety.  
 
High trait anxiety and (benign) breast disease 
Trait anxiety concerns differences in individuals in the disposition to respond to 
stressful situations, such as a possible diagnosis of BC, with varying amounts of 
stress.16 Previous studies have revealed a negative impact of the personality 
characteristic trait anxiety on state anxiety, depressive symptoms, and QoL in 
women with BC and/or BBD.17-21 We believe that a tailor-made follow-up protocol 
would be useful to prevent adverse psychological consequences in women with 
HTA during and after the diagnostic process for possibly having BC.  
Therefore, the second part of this thesis focuses on the impact of the personality 
characteristic trait anxiety on health care utilization, psychological distress (state 
anxiety, depressive symptoms), and QoL in women with benign or malignant 
(breast) disease. To our knowledge, examining the impact of HTA on health care 
utilization has not been done before in women diagnosed with BC or BBD.  
Furthermore, we hypothesized that the severity of diagnosis, i.e. being confronted 
with a possible malignant breast disease, will also be an important predictor for 
psychological distress, in addition to the personality characteristic trait anxiety. In 
order to study this hypothesis, we compared women suspected of having BC or 
BBD with women with gallstone disease awaiting an elective laparoscopic 
cholecystectomy. The group of women with gallstone disease was chosen, 
because it was previously found that HTA had a negative impact on QoL and 
persisting symptoms in this group.22,23  
Such a comparative study to assess the influence of the personality and the 
combination of personality and diagnosis on QoL and psychological distress has 
not been done before. Before implementing a protocol for women with breast 
disease and HTA, it is important to know whether women with HTA experience 
higher levels of distress and impairment of QoL, irrespective of the diagnosis they 
are facing or in particular when suspected of having BC.  
 
In chapter five we evaluated the health care utilization and its predictors in women 
diagnosed with BC or BBD. Health care utilization was measured during the first 
year following the diagnostic work-up for breast disease. Health care utilization 
was divided in visits to the general practitioner, the medical doctor or psychosocial 
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care. Women diagnosed with BC (N=151) were compared with women with BBD 
(N=440). Overall, women with BC were visiting the general practitioner, the 
medical doctor or psychosocial care more frequently than women with BBD. This 
higher health care utilization in women with BC is a consequence of the BC 
(adjuvant) treatment and follow-up protocol. In the BBD group, in women with HTA 
increased overall health care utilization was found compared with women with 
NHTA. In women with BC and HTA only more use of psychosocial care was found. 
Regression analysis showed that lower scores on QoL predicted health care 
utilization in BBD. In women with BC (adjuvant) treatment predicted health care 
utilization. Thus, the most important factors for increased health care utilization 
were HTA and lower scores on QoL, in particular in women with BBD. In women 
with BC a higher use of psychosocial care was found in chronically anxious 
women.  
 
In chapter six we analysed whether high state anxiety and depressive symptoms 
in women with BC or BBD are determined solely by the personality characteristic 
trait anxiety, or whether it is caused by personality in combination with the severity 
of diagnosis, a possible life-threatening disease (i.e. BC). To examine this, we 
compared women with breast disease with women with a non life-threatening 
disease, i.e. gallstone disease. Women with breast disease were included before 
diagnosis was known (BC or BBD), and women with gallstone disease before the 
elective laparoscopic cholecystectomy. Prior to diagnosis women with BC or BBD 
(N=357) were more anxious compared with gallstone disease (N=128). Scores on 
depressive symptoms at baseline were higher in women with BC or BBD 
compared with gallstone disease. At six months scores on depressive symptoms 
remained higher in BC (N=152) compared with women with gallstone disease. 
Women with HTA scored unfavourably on state anxiety and depressive symptoms 
at all time points compared with women with NHTA, especially women with BC. 
Thus, women who were confronted with the possibility of having BC, experienced 
higher state anxiety and depressive symptoms than women with gallstone disease. 
These effects were heightened in women with HTA. It is the combination of the 
diagnosis BC and HTA that evoked the highest levels of distress.  
 
In chapter seven the impact of trait anxiety and/or the severity of diagnosis on 
QoL was examined. We compared women with BC or BBD with women with 
gallstone disease. Women with HTA scored unfavourably on fatigue and QoL 
compared with women with NHTA at baseline and at six months. At referral women 
with gallstone disease scored lower on several domains of QoL compared with BC, 
regardless of the score on trait anxiety. At six months these scores significantly 
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increased in the gallstone disease group with NHTA, probably due to the relief of 
symptoms after the operation. In women diagnosed with BBD and NHTA the 
scores on fatigue and physical QoL improved at six months, which can be 
explained by the relief that BC was not found. Women diagnosed with BC and 
NHTA experienced impairment in physical QoL and fatigue six months after the 
surgery. These findings were not unexpected because of the effects of BC 
diagnosis and its treatment. The most important factors of influence on QoL were 
HTA and the change in scores on fatigue across time. Thus, the course of QoL and 
fatigue during follow-up was significantly different for each diagnosis. Especially, 
HTA had a negative impact on patients’ QoL and fatigue. In particular, the 





Nowadays, BC screening has become standard of practice in the Western World. 
The BC screening program was implemented to obtain earlier detection of BC with 
the potential to reduce BC mortality. In the Netherlands, several studies have 
demonstrated that BC screening contributes to the decline of BC mortality.24-26 In 
other countries with long-standing BC screening programs, the beneficial effect of 
screening on BC mortality was also confirmed.27 However, if reduction in BC 
mortality is due to screening, one would expect that there is a decrease in 
diagnosing advanced BC. This is not the case during the 12 years of biennial 
screening in the Netherlands.28 Moreover, it is suggested that BC screening has 
only a little detectable impact on BC mortality.1-3 This conflicting evidence is partly 
explained because of the fact that the reduction of BC mortality was found in 
suboptimal performed trials, and that the trials with adequate randomisation did not 
reveal any impact on BC mortality.3 Several studies suggested that the decline in 
BC mortality is accomplished only by the improvements of adjuvant BC 
treatment.29-31 As a consequence, recent publications have been questioning 
whether the benefits still outweigh the harms of the BC screening program.1-10 To 
contribute to this ongoing discussion, we examined the impact of an ASM on 
women’s psychological distress and QoL. 
The first part of this thesis reveals that the impact of an ASM on state anxiety, 
depressive symptoms and QoL is substantial and causes a serious problem. Not 
only chronically anxious women experienced the diagnostic process for breast 
disease as a great emotional burden. Also women not prone to anxiety reported 
significant adverse psychological consequences during and after the diagnostic 
work-up for an ASM. In 79 per cent of the women with HTA abnormal levels of 
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anxiety were found prior to diagnosis, as well as in up to 30 per cent of the women 
with NHTA. The fact that women with NHTA are also severely affected implies that 
being recalled for further diagnostic procedures after an ASM is a serious 
psychological problem. These women do not have a high propensity to anxiety, 
thus, the abnormal levels of anxiety are directly caused by the threat of possibly 
having BC. In our opinion, these findings are unacceptable, because we have 
found not only short-term effects, but also long-term consequences. Even though 
the distress was decreased one month after diagnosis, a diminished QoL was still 
found one year later, regardless of the score on trait anxiety. This implies that the 
psychological distress is not just a temporary problem. Moreover, women with an 
FP and HTA reported even more impairment in QoL after one year than women 
with BC and HTA. This ongoing impairment in QoL can be considered as a long-
term consequence of the experienced distress during the diagnostic work-up after 
an ASM. The long-term effects after an ASM are confirmed by the fact that 55 per 
cent of the women frequently visited the outpatient surgical clinic in the first year 
after the FP. Apparently, these women needed more reassurance to confirm that 
their diagnosis was not BC. This higher need for reassurance is not unexpected, 
as being recalled without any symptom is very alarming. These women did not 
have a palpable lump in the breast or any complaints and so were not expecting an 
ASM followed by further additional (invasive) investigations. This might explain the 
increased visits during the first year after diagnosis. These findings confirm the 
severe impact of an ASM on the psychological health of women attending the BC 
screening program. The results of this thesis are in concordance with previous 
reviews describing the adverse psychological consequences after an FP.12-15 In 
contrast to the majority of the included studies in these reviews, in our study the 
questionnaires were completed before the diagnosis BC or BBD was known. This 
renders a true baseline measurement and makes our findings even more 
convincing.  
 
The second part of this thesis examined whether women with HTA are always 
experiencing increased distress and impairment in QoL, or whether the diagnosis 
itself, i.e. BC, is also an important predictive factor. Our findings are in accordance 
with previous studies, revealing a negative impact of HTA on distress and QoL in 
women with BC or BBD.17-21 Moreover, we found that in women with HTA the 
possible diagnosis BC is much more threatening than undergoing surgery for 
gallstone disease. Before diagnosis is known, in the group of women with HTA, 
women with BC were more anxious than women with BBD, and women with BBD 
were more anxious than women with gallstone disease. Thus, it is the combination 
of the diagnosis BC and HTA, which causes the highest levels of anxiety. In 
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addition, HTA had a significant impact on health care utilization in women 
diagnosed with BBD one year after the diagnostic work-up. Furthermore, in women 
confronted with the possibility of having BC, the impact of HTA on QoL was less 
important than in women with gallstone disease. In women with BC other factors 
were also important for determining QoL, such as increased fatigue. It is the 
severe impact of the possible diagnosis BC that determines directly the increased 
distress, impairment in QoL and health care utilization, and these findings are 
heightened in women with HTA. Therefore, these results confirm that the negative 
impact of an ASM on distress and QoL in women with HTA is caused by the 
combination of being suspected of having BC and HTA, instead of only by the 
HTA. 
 
This thesis shows that being diagnosed with an ASM evokes serious distress and 
impairment in QoL, regardless of the score on trait anxiety. In the Netherlands, the 
risk for an FP is 9 per cent when attending 13 screening rounds.32 This relatively 
low number is explained by the much lower recall and FP rate in the Netherlands 
compared with other countries.32 For instance, the risk for an FP is estimated to be 
49 per cent after ten mammograms in the United States and up to 21 per cent in 
Norway.33,34 Because of this higher chance of an FP, the adverse psychological 
consequences found in this thesis are expected to be an even more serious 
problem in the United States. Since BC screening is offered to healthy women, we 
believe that the disadvantages should be kept to a minimum. Obviously, every 
screening program has certain harms, but the benefits should significantly 
outweigh these harms. However, in this thesis we found adverse psychological 
problems in all women referred after an ASM. As it concerns healthy women 
without symptoms or signs of breast disease, we consider these effects as severe 
and undesirable consequences of BC screening. Especially, considering the minor 
effect on BC mortality previously found1-3, we believe that the negative 
consequences after an ASM found in this thesis are really unnecessary and thus 
unacceptable. Therefore, in our opinion the balance between the advantages and 
disadvantages of the BC screening program can no longer be considered in favour 
of screening. Based on previous findings and this thesis we agree with several 
authors who already made a plea to re-evaluate the rationale of the BC screening 
program!5,10,30   
 
Methodological limitations of the study 
 
The study has a number of methodological limitations. The first shortcoming is that 
we included women referred after an ASM to investigate the impact of the BC 
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screening program. However, in the Netherlands, the recall rate is approximately 2 
per cent.35 Thus, we have no information on the amount of distress in women who 
are diagnosed with a normal screening mammogram. Preferably, all women should 
complete the questionnaires before the screening mammogram is done. This 
would be an even better baseline measurement than we have done in this present 
study, i.e. after referral, but before diagnosis was known.  
One of the other limitations of the study is the participation rate. Overall, the 
participation rate was approximately 65 per cent. Reasons for not participating in 
the study were the length of the questionnaires, the amount of stress prior to 
diagnosis and as a consequence, the feeling not being able to complete the 
questionnaires. Therefore, our results may well be an underestimation of the 
experienced distress and impairment of QoL, because it appears that more 
distressed women did not participate in our study.  
Another drawback is the drop-out rate of the study, which was approximately 35 
per cent. Women who did not complete all questionnaires during follow-up were 
excluded from further analysis. Baseline demographics and personality were 
compared between drop-outs and women who remained in the study. In particular, 
in the drop-out group more women were diagnosed with BBD or with HTA. As a 
consequence, we can assume that our results would have been even more 
convincing if those women with HTA had completed all questionnaires during 
follow-up.  
HCU was measured with self-reported use of health care during the first year after 
the diagnosis BBD or BC. Therefore, an underestimation of health care utilization 
is possible because of the effort of recalling all medical contacts in the previous 12 
months. Thus, our results would probably have been more convincing if the health 
care utilization was prospectively followed and objectively measured. However, in 
both groups, BC and BBD, the same method was applied. 
Overall, the follow-up period in our study was up to 12 months. We believe that a 





This thesis shows that the impact of the BC screening program on distress and 
QoL is a serious problem after an ASM, both in women with HTA or NHTA. Based 
on these findings we advocate that as long as screening continues two important 
topics should be improved. Firstly, the decision to participate to the BC screening 
program is based upon information in favour of screening without mentioning the 
serious disadvantages.3,6-8,36,37 As a result women overestimate their risk of BC 
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and the benefits of screening and are not aware of the possible dangers.38,39 We 
recommend that women are informed correctly concerning the benefits ánd risks of 
the BC screening program, in particular mentioning the risk for overdiagnosis and 
the substantial psychological consequences after an FP. With this balanced 
information women will be able to choose whether or not to accept the invitation to 
the BC screening program.  
 
Secondly, we recommend identifying women who are at risk for the adverse 
psychological effects, in particular women with HTA, with a psychometrically sound 
self-report questionnaire at intake. These women can then be offered a tailor-made 
follow-up protocol, which should be developed for women with HTA. Through this 
individual approach, women who need more support can be recognised and can 
be offered psychosocial interventions that focus on learning how to cope with these 
stressful events. 
 
Future perspectives  
 
Based on the findings of this thesis it is important to improve the information 
provided to women attending the BC screening program. Future research will be 
necessary to investigate the impact of providing evidence based information on the 
attendance rate and the experienced distress and QoL. Furthermore, a longer 
follow-up period than one year will be required to measure how long the negative 
impact of an ASM persists. Also, the effect of an ASM on the re-attendance rate 
and the health care utilization should be examined.  
 
In addition, women at risk for the adverse psychological consequences after an 
ASM should be offered a tailor–made follow-up protocol when necessary. It is 
important to examine the impact of this protocol on distress, QoL and health care 
utilization during and after the diagnostic work-up for breast disease. In this way 
we will be able to investigate the implementation and if necessary can adjust this 
protocol.  
Also, women should be identified who will benefit from this tailor-made follow-up 
protocol. Women with HTA can be assessed with the short version of the STAI-
Trait questionnaire.16 However, also women with NHTA are at risk for serious 
psychological effects after an FP. These women should be offered a validated self-
report questionnaire to screen women at risk for adverse psychological problems 
diagnosed with BBD. Recently, the Psychosocial Distress Questionnaire-Breast 
Cancer was developed for women with early-stage BC.40,41 It was found that this is 
an easy and useful instrument to screen psychosocial problems in women with 
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BC.40,41 For women diagnosed with BBD after an ASM, this questionnaire should 
be tested and validated before it can be used in this group of women.  
 
To contribute to the ongoing discussion concerning the BC screening program 
future research should focus on several important topics.  
Firstly, in this study, women were included who were referred after an ASM for 
further additional investigations. The recall rate in the Netherlands is only 2 per 
cent.35 This implies that we have no information about the experienced distress 
and QoL in women who are not referred (98 per cent). We are interested in the 
short- and long-term experienced distress and QoL in those women with a normal 
screening mammogram. We suggest to investigate (the impact of HTA on) 
distress, health care utilization and concerns about possibly having BC before and 
after attending the BC screening program in this particular group of women. Thus, 
all women should be asked to complete the questionnaires before undergoing the 
screening mammogram. When the results of the screening mammogram are 
known, all women should fill in the questionnaires again, to determine the 
psychological effects of being referred or reassured after a screening 
mammogram.   
 
Secondly, we are interested in women recalled after an ASM, who undergo further 
additional investigations, such as a repeat mammogram, eventually followed by 
biopsies or a MRI. In our experience, undergoing a MRI often leads to an extra 
ultrasound investigation of the breast, which is frequently completed by a biopsy. In 
clinical practice, some women are then recalled again after 6 months for a repeat 
mammogram or MRI to achieve even more reassurance about the diagnosis BBD. 
In the Netherlands, only in 70 per cent of the women the diagnosis is known within 
three months after the ASM.35 We expect that the longer the period of additional 
(invasive) investigations is, and thus the longer women have to wait for the final 
diagnosis, the more distress these women will experience. We believe it is 
necessary to examine the impact of the further (invasive) investigations on 
distress, QoL and health care utilization in women recalled after an ASM, and to 
offer these women extra psychosocial support when necessary. In addition, the 
diagnostic process has to be evaluated to examine the possible delay during this 
process, and the unnecessary or ineffective investigations. With this information it 
will be feasible to improve the diagnostic process in women after an ASM.  
 
Thirdly, we believe it is important to determine the adverse psychological 
consequences in women with screen-detected ductal carcinoma in situ (DCIS). 
Overdiagnosis is an important problem of BC screening, which means detecting 
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lesions that would otherwise never have been identified clinically. Overdiagnosis 
due to BC screening was found in a meta-analysis in up to 52 per cent, of which 20 
per cent was DCIS.42 The overdiagnosis in the Netherlands has been calculated 
with a mathematical model, and is estimated to be 10 per cent.43 This is partly 
explained by the lower recall and FP rate in the Netherlands35 compared with other 
countries. DCIS accounts for 16 per cent of all screen-detected cancers in the 
Netherlands.28 Despite their generally favourably prognosis, women treated for 
DCIS report increased distress and impaired mental health and concerns about 
recurrence and death, similar to women with BC.44,45 So far, analysing the impact 
of the personality characteristic trait anxiety on distress and QoL has not been 
performed before in this particular group of women. Therefore, we suggest 
examining the short- and long-term psychological consequences in women with 
screen-detected DCIS and analyse the impact of HTA on these effects. In addition, 
we recommend to improve the provided information concerning treatment options 
and prognosis of screen-detected DCIS. In addition, the effect of providing 
evidence based information in women with screen-detected DCIS on distress, QoL 
and health care utilization should be examined.  
 
Finally, we are interested in women who are diagnosed with BC during the interval 
of the screening program. In the Netherlands, annually 13000 women are 
diagnosed with BC, of which 4500 are screen-detected BC, and 1800 are 
considered as interval BC.35 Of the interval BC at least 25 per cent is reviewed as 
a false-negative screening mammogram in the previous round.32 We believe it is 
important to investigate the amount of distress and impairment in QoL in this 
particular group of women with interval BC. Because these women were reassured 
after a normal screening mammogram, but are nevertheless diagnosed with BC. 
We expect that these women are being more concerned and thus, are seeking 
more reassurance despite the regular follow-up protocol, and as a consequence 
have an increased health care utilization. When examining the exact needs and 
concerns of this group of women it will possible to offer a tailor-made follow-up 
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Bevolkingsonderzoek naar borstkanker en de psychologische effecten 
In 1960 werd het bevolkingsonderzoek naar borstkanker (BOB) geïmplementeerd 
met als doel vroege detectie van borstkanker (BK) en reductie van de BK 
mortaliteit te bewerkstelligen. Recente studies hebben echter gesuggereerd dat 
screening zeer weinig invloed heeft op de BK mortaliteit.1-3 Dit terwijl het BOB 
belangrijke nadelen kent, zoals overdiagnose, overbehandeling en een fout-positief 
screenings mammogram.3,4 Daaropvolgend hebben recente studies de screening 
ter discussie gesteld, waarbij men zich afvraagt of de voordelen van het BOB nog 
wel opwegen tegen de nadelen.1-10   
Om te kunnen bijdragen aan deze discussie omtrent het BOB, was het doel van 
het eerste deel van dit proefschrift te bepalen wat de impact is van een afwijkend 
screenings mammogram op angst, depressieve symptomen en kwaliteit van leven 
(KvL). Eveneens werd de impact van de karaktertrek angst op deze 
psychologische parameters geanalyseerd. De karaktertrek angst betreft de neiging 
om met een verhoogde angstbeleving te reageren op bedreigende situaties, zoals 
een mogelijke diagnose BK.11 
 
In hoofdstuk twee zijn twee groepen met een afwijkend screenings mammogram 
vergeleken, de groep met de uiteindelijke diagnose BK (N=152) en de groep met 
een fout-positief screenings mammogram (N=233). In zijn algemeenheid scoren 
vrouwen met BK hoger op angstbeleving en slechter op KvL dan vrouwen met een 
fout-positief screenings mammogram. Vrouwen met de karaktertrek angst hebben 
een hoge angstbeleving en verslechtering van KvL, ongeacht de diagnose fout-
positief screenings mammogram of BK. Doorverwezen worden met een afwijkend 
screenings mammogram leidt tot meer histologische biopten en frequente 
poliklinische bezoeken in de groep met een fout-positief screenings mammogram.   
 
In hoofdstuk drie is onderzocht of de timing van een afwijkend screenings 
mammogram van invloed is op de psychologische parameters. We hebben 
vrouwen vergeleken die zijn doorverwezen na een eerste screenings mammogram 
(N=186) met vrouwen die al eerder een screenings mammogram hebben 
ondergaan (N=296). Bij alle vrouwen wordt een hoge score op angstbeleving 
gevonden voordat de diagnose bekend is. Deze effecten worden versterkt door de 
karaktertrek angst. Doorverwezen worden na een eerste screenings mammogram 
veroorzaakt een nog hogere score op angstbeleving, met name bij vrouwen zonder 





NEDERLANDSE	  SAMENVATTING	   119	  




Bevolkingsonderzoek naar borstkanker en de psychologische effecten 
In 1960 werd het bevolkingsonderzoek naar borstkanker (BOB) geïmplementeerd 
met als doel vroege detectie van borstkanker (BK) en reductie van de BK 
mortaliteit te bewerkstelligen. Recente studies hebben echter gesuggereerd dat 
screening zeer weinig invloed heeft op de BK mortaliteit.1-3 Dit terwijl het BOB 
belangrijke nadelen kent, zoals overdiagnose, overbehandeling en een fout-positief 
screenings mammogram.3,4 Daaropvolgend hebben recente studies de screening 
ter discussie gesteld, waarbij men zich afvraagt of de voordelen van het BOB nog 
wel opwegen tegen de nadelen.1-10   
Om te kunnen bijdragen aan deze discussie omtrent het BOB, was het doel van 
het eerste deel van dit proefschrift te bepalen wat de impact is van een afwijkend 
screenings mammogram op angst, depressieve symptomen en kwaliteit van leven 
(KvL). Eveneens werd de impact van de karaktertrek angst op deze 
psychologische parameters geanalyseerd. De karaktertrek angst betreft de neiging 
om met een verhoogde angstbeleving te reageren op bedreigende situaties, zoals 
een mogelijke diagnose BK.11 
 
In hoofdstuk twee zijn twee groepen met een afwijkend screenings mammogram 
vergeleken, de groep met de uiteindelijke diagnose BK (N=152) en de groep met 
een fout-positief screenings mammogram (N=233). In zijn algemeenheid scoren 
vrouwen met BK hoger op angstbeleving en slechter op KvL dan vrouwen met een 
fout-positief screenings mammogram. Vrouwen met de karaktertrek angst hebben 
een hoge angstbeleving en verslechtering van KvL, ongeacht de diagnose fout-
positief screenings mammogram of BK. Doorverwezen worden met een afwijkend 
screenings mammogram leidt tot meer histologische biopten en frequente 
poliklinische bezoeken in de groep met een fout-positief screenings mammogram.   
 
In hoofdstuk drie is onderzocht of de timing van een afwijkend screenings 
mammogram van invloed is op de psychologische parameters. We hebben 
vrouwen vergeleken die zijn doorverwezen na een eerste screenings mammogram 
(N=186) met vrouwen die al eerder een screenings mammogram hebben 
ondergaan (N=296). Bij alle vrouwen wordt een hoge score op angstbeleving 
gevonden voordat de diagnose bekend is. Deze effecten worden versterkt door de 
karaktertrek angst. Doorverwezen worden na een eerste screenings mammogram 
veroorzaakt een nog hogere score op angstbeleving, met name bij vrouwen zonder 
de karaktertrek angst.  
 
120	   CHAPTER	  9	  
	  
	  
In hoofdstuk vier zijn vrouwen met de diagnose benigne borstafwijking 
doorverwezen na een afwijkend screenings mammogram (N=363) vergeleken met 
vrouwen doorverwezen met een palpabele benigne afwijking in de borst (N=401). 
Vrouwen doorverwezen na een afwijkend screenings mammogram ervaren meer 
angst en depressieve symptomen vlak voordat de diagnose gesteld wordt dan 
vrouwen met een palpabele afwijking in de borst. De vrouwen met een afwijkend 
screenings mammogram scoren ook slechter op KvL tot een jaar na het stellen van 
de diagnose. Deze effecten worden met name gevonden bij vrouwen zonder de 
karaktertrek angst.  
 
Karaktertrek angst bij vrouwen met een (benigne) borstafwijking  
Eerdere studies hebben de negatieve impact van de karaktertrek angst op 
angstbeleving, depressieve symptomen en KvL aangetoond bij vrouwen met BK 
en een benigne borstafwijking.12-16 In het tweede deel van dit proefschrift ligt de 
focus op de impact van de karaktertrek angst op de zorgconsumptie en op de mate 
van angstbeleving, depressieve symptomen en KvL bij vrouwen met benigne of 
maligne (borst) ziekte. Hiermee hebben we onderzocht of de eerdere bevindingen 
ten aanzien van de karaktertrek angst veroorzaakt worden door alleen het karakter 
of ook door de combinatie van de karaktertrek angst en de eventuele diagnose BK. 
Hiervoor hebben we vrouwen met de verdenking van BK vergeleken met vrouwen 
die gepland werden voor een operatie vanwege galstenen. De groep vrouwen met 
galsteenziekte werd gekozen omdat in deze groep reeds eerder was aangetoond 
dat de karaktertrek angst een negatieve invloed heeft op KvL en persisterende 
klachten na de operatie.17,18 
 
In hoofdstuk vijf hebben we de zorgconsumptie vergeleken tussen vrouwen met 
BK (N=151) en een benigne borstafwijking (N=440) gedurende het jaar na de 
diagnose. Vrouwen met een benigne borstafwijking met de karaktertrek angst 
hebben een hogere zorgconsumptie dan vrouwen met een benigne borstafwijking 
zonder de karaktertrek angst. Bij vrouwen met BK en de karaktertrek angst werd 
meer gebruik van psychosociale zorg gevonden. Belangrijkste voorspeller voor 
zorgconsumptie bij vrouwen met een benigne borstafwijking zijn de karaktertrek 
angst en lagere scores voor KvL. Bij vrouwen met BK is de (adjuvante) 
behandeling de belangrijkste voorspeller voor zorgconsumptie.  
 
In hoofdstuk zes zijn vrouwen vergeleken met BK (N=152), een benigne 
borstafwijking (N=205) en galsteenziekte (N=128) om de impact van de 
karaktertrek angst en de diagnose op angst en depressieve symptomen te 
bepalen. Vrouwen met de verdenking van BK ervaren meer angstbeleving en 
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depressieve symptomen dan vrouwen met galsteenziekte. Deze effecten worden 
versterkt door de karaktertrek angst. Het is de combinatie van BK en de 
karaktertrek angst welke de hoogste mate van stress veroorzaakt.  
 
In hoofdstuk zeven zijn vrouwen vergeleken met BK, een benigne borstafwijking 
en galsteenziekte om de impact van de karaktertrek angst en de diagnose op KvL 
te bepalen. Bij vrouwen met galsteenziekte nemen de scores van meerdere 
domeinen van KvL toe na de operatie, vooral bij vrouwen zonder de karaktertrek 
angst. Bij vrouwen met een benigne borstafwijking zonder de karaktertrek angst 
neemt de fysieke KvL toe en verbetert de vermoeidheid. Bij vrouwen met BK 
zonder de karaktertrek angst verslechtert de fysieke KvL en de vermoeidheid. 
Vrouwen met de karaktertrek angst scoorden slechter op KvL en vermoeidheid op 
beide meetmomenten dan vrouwen zonder de karaktertrek angst. Met name de 





Tegenwoordig is screenen voor borstkanker een vanzelfsprekendheid geworden in 
de Westerse wereld. Het BOB heeft als belangrijkste doel vroege detectie, om 
daarmee de mortaliteit van BK te reduceren. In Nederland hebben meerdere 
studies aangetoond dat het BOB bijdraagt aan de afname van de mortaliteit van 
BK.19-21 In andere landen met een langer bestaand BOB werden deze gunstige 
effecten bevestigd.22 Echter, als het BOB vroege detectie bewerkstelligt, dat wil 
zeggen een kleinere tumor ontdekt met minder of geen metastasen, dan verwacht 
men dat er een afname is van het aantal vergevorderde stadia van BK. Dit is niet 
het geval gedurende 12 jaar screening in Nederland.23 Daarnaast is recent nog 
gesuggereerd dat screening een minimaal effect heeft op de BK mortaliteit.1-3 Dit 
conflicterende bewijs wordt deels verklaard doordat de eerdere gevonden afname 
in BK sterfte is aangetoond in onderzoeken van matige kwaliteit, terwijl de trials 
met adequate randomisatie geen effect van screening op de mortaliteit van BK 
hebben bewezen.3 Meerdere studies hebben gesuggereerd dat de afname in de 
sterfte van BK bewerkstelligd wordt door de aanzienlijke verbetering van de 
adjuvante behandeling van BK.22-26  
Het eerste deel van dit proefschrift laat zien dat de impact van een afwijkend 
screenings mammogram op angstbeleving, depressieve symptomen en KvL 
aanzienlijk is en een serieus probleem veroorzaakt. Niet alleen vrouwen met de 
karaktertrek angst ervaren het diagnostisch proces voor borstafwijkingen als een 
grote emotionele belasting. Ook vrouwen zonder de karaktertrek angst ervaren 
9
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depressieve symptomen dan vrouwen met galsteenziekte. Deze effecten worden 
versterkt door de karaktertrek angst. Het is de combinatie van BK en de 
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Tegenwoordig is screenen voor borstkanker een vanzelfsprekendheid geworden in 
de Westerse wereld. Het BOB heeft als belangrijkste doel vroege detectie, om 
daarmee de mortaliteit van BK te reduceren. In Nederland hebben meerdere 
studies aangetoond dat het BOB bijdraagt aan de afname van de mortaliteit van 
BK.19-21 In andere landen met een langer bestaand BOB werden deze gunstige 
effecten bevestigd.22 Echter, als het BOB vroege detectie bewerkstelligt, dat wil 
zeggen een kleinere tumor ontdekt met minder of geen metastasen, dan verwacht 
men dat er een afname is van het aantal vergevorderde stadia van BK. Dit is niet 
het geval gedurende 12 jaar screening in Nederland.23 Daarnaast is recent nog 
gesuggereerd dat screening een minimaal effect heeft op de BK mortaliteit.1-3 Dit 
conflicterende bewijs wordt deels verklaard doordat de eerdere gevonden afname 
in BK sterfte is aangetoond in onderzoeken van matige kwaliteit, terwijl de trials 
met adequate randomisatie geen effect van screening op de mortaliteit van BK 
hebben bewezen.3 Meerdere studies hebben gesuggereerd dat de afname in de 
sterfte van BK bewerkstelligd wordt door de aanzienlijke verbetering van de 
adjuvante behandeling van BK.22-26  
Het eerste deel van dit proefschrift laat zien dat de impact van een afwijkend 
screenings mammogram op angstbeleving, depressieve symptomen en KvL 
aanzienlijk is en een serieus probleem veroorzaakt. Niet alleen vrouwen met de 
karaktertrek angst ervaren het diagnostisch proces voor borstafwijkingen als een 
grote emotionele belasting. Ook vrouwen zonder de karaktertrek angst ervaren 
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negatieve psychologische effecten tijdens en na het diagnostische proces na een 
afwijkend screenings mammogram. Bij 79 procent van de vrouwen met de 
karaktertrek angst werden abnormale waarden op angstbeleving gevonden 
voordat de diagnose gesteld werd, maar ook bij 30 procent van de vrouwen zonder 
de karaktertrek angst. Het feit dat vrouwen zonder de karaktertrek angst ook 
angstig worden impliceert dat doorverwezen worden na een afwijkend screenings 
mammogram een serieus psychologisch probleem veroorzaakt. Deze vrouwen 
hebben niet de neiging om snel angstig te worden, waardoor de abnormale 
waarden op angstbeleving direct worden veroorzaakt door de verdenking op BK. 
Ons inziens zijn deze bevindingen een ernstig probleem, met name omdat we niet 
alleen korte termijn effecten hebben gevonden, maar ook lange termijn 
consequenties. Ondanks dat de hogere scores voor angstbeleving en depressieve 
symptomen een maand na de diagnose waren afgenomen, was er wel sprake van 
een verslechtering van KvL tot een jaar na de diagnose, ongeacht de score voor 
de karaktertrek angst. Dit betekent dat het psychologische probleem na een 
afwijkend screenings mammogram niet van tijdelijke aard is. De verslechtering van 
KvL zal een gevolg zijn van de ernstige stress welke vrouwen hebben ervaren ten 
tijde van het diagnostisch proces. De lange termijn effecten worden bevestigd door 
het hoge aantal vrouwen (55 procent) dat de polikliniek nog heeft bezocht 
gedurende het eerste jaar na een fout-positief screenings mammogram. Blijkbaar 
zijn deze vrouwen niet voldoende gerustgesteld als blijkt dat ze toch geen BK 
hebben na een afwijkend screenings mammogram. Deze behoefte aan meer 
geruststelling is niet onverwacht, aangezien de vrouwen worden doorverwezen 
zonder klachten te hebben van de borst en dat is zeer verontrustend. Deze 
vrouwen hebben immers geen palpabele afwijking in de borst bemerkt of andere 
klachten en hadden een afwijkend screenings mammogram totaal niet verwacht, 
laat staan alle extra (invasieve) onderzoeken welke worden verricht in verband met 
het afwijkend screenings mammogram. Ook deze bevindingen bevestigen de 
ernstige impact van een afwijkend screenings mammogram op het psychisch 
welbevinden. De resultaten zijn in overeenstemming met eerdere reviews ten 
aanzien van de nadelige psychologische gevolgen van een afwijkend screenings 
mammogram.27-30 In tegenstelling tot de meeste studies beschreven in deze 
reviews, is in onze studie de eerste vragenlijsten set ingevuld voordat de diagnose 
bekend was. Dit betekent een echte baseline meting, waardoor onze bevindingen 
van nog meer waarde zijn.  
 
Het tweede deel van dit proefschrift toont aan dat vrouwen met de karaktertrek 
angst slechter scoren op angstbeleving, depressieve symptomen en KvL als zij 
geconfronteerd worden met de mogelijke diagnose BK in vergelijking met vrouwen 
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met galsteenziekte. De karaktertrek angst had een significante impact op 
zorgconsumptie een jaar later bij vrouwen met een benigne borstafwijking. De 
impact van de karaktertrek angst op KvL was minder belangrijk bij vrouwen met BK 
of een benigne borstafwijking dan bij galsteenziekte. Hieruit volgt dat de nadelige 
gevolgen na een afwijkend screenings mammogram gevonden bij vrouwen met de 
karaktertrek angst worden veroorzaakt door de combinatie van verdenking op BK 
en de karaktertrek angst, en niet alleen door de karaktertrek angst zelf.  
 
Dit proefschrift laat zien dat een afwijkend screenings mammogram ernstige 
psychologische gevolgen heeft, ongeacht de karaktertrek angst. In Nederland is de 
kans op een fout-positief screenings mammogram 9 procent als een vrouw 13 keer 
meedoet aan de screening.31 In vergelijking met andere landen is deze kans 
relatief laag. Dit wordt verklaard door het lagere doorverwijs percentage en de 
lagere kans op een fout-positief screenings mammogram in Nederland.31 De kans 
op een fout-positief screenings mammogram wordt geschat op 49 procent na 10 
mammogrammen in de Verenigde Staten en op 21 procent in Noorwegen.32,33 De 
verwachting is dat de psychologische nadelen gevonden in dit proefschrift nog 
ernstiger zullen zijn in bijvoorbeeld de Verenigde Staten gezien de hogere kans op 
een fout-positief screenings mammogram.  
Aangezien het BOB aangeboden wordt aan gezonde vrouwen, is het belangrijk dat 
de nadelen van de screening tot een minimum beperkt blijven. Uiteraard heeft elk 
screenings programma bepaalde nadelen, maar de voordelen moeten wel 
ruimschoots opwegen tegen de nadelen. Dit proefschrift toont aan dat nadelige 
psychologische gevolgen bij alle vrouwen na een afwijkend screenings 
mammogram werden gevonden. Aangezien het gezonde vrouwen betreft zonder 
klachten of symptomen van de borst, beschouwen wij deze gevolgen als ernstige 
en onnodige effecten van het BOB. Met name omdat er recent is aangetoond dat 
de screening een minimale impact heeft op de BK mortaliteit1-3, zijn wij van mening 
dat de balans tussen de voor- en nadelen van het BOB niet meer ten faveure van 
screening is te noemen. Op basis van eerdere bevindingen en dit proefschrift 
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Op basis van de bevindingen van dit proefschrift willen wij bewerkstelligen dat 
zolang het BOB continueert, de informatievoorziening omtrent het BOB verbeterd 
moet worden. Op dit moment is de informatie betreffende het BOB enkel ten 
faveure van screening zonder de ernstige nadelen te noemen.3,6-8,34,35 Mede 
hierdoor overschatten vrouwen hun risico op BK en de voordelen van screening en 
zijn dus niet correct geïnformeerd.36,37 Wij pleiten voor een goede 
informatievoorziening betreffende voor- en nadelen van het BOB. Daarbij moet 
vooral ook het risico op overdiagnose en de aanzienlijke psychologische 
consequenties na een fout-positief screenings mammogram genoemd worden. Met 
behulp van deze betere informatievoorziening kunnen vrouwen beter beslissen of 
zij willen deel nemen aan het BOB.  
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Allereerst bijzonder veel dank aan alle vrouwen die hebben meegewerkt aan dit 
onderzoek, zonder hen was dit proefschrift niet tot stand gekomen! In een periode 
met zeer veel onzekerheid en zorgen hebben zij toch de moeite genomen om de 
vragenlijsten voor onze studie in te vullen, waarvoor heel veel dank! Hopelijk zal dit 
proefschrift bijdragen aan een verbetering van de zorg voor vrouwen met een 
(benigne) borstafwijking. 
  
Daarnaast wil ik een aantal mensen persoonlijk bedanken: 
  
Professor dr. J.A. Roukema, beste Anne, dankzij Hermien ben ik bij jou terecht 
gekomen en werd ik met open armen ontvangen om onderzoek bij jullie te komen 
doen. Bijzonder enthousiast was je over mijn ideeën voor het cortisol onderzoek, 
uiteindelijk heeft mijn proefschrift een ander (nog interessanter!) onderwerp 
gekregen dan we uiteindelijk hadden gedacht. Veel dank voor de zeer goede 
samenwerking en jouw briljante ideeën voor het onderzoek. Jouw bevlogenheid 
om ook de nadelen van het bevolkingsonderzoek borstkanker aan het licht te 
brengen is zeer inspirerend geweest! Het feit dat jullie in Tilburg werken was alles 
behalve een probleem dankzij de zeer snelle mailwisseling, waardoor we in een 
hoog tempo dit proefschrift hebben kunnen schrijven. Bijzonder veel dank voor de 
gegeven kans en het vertrouwen om onderzoek met jullie te mogen doen!  
 
Professor dr. J. De Vries, beste Jolanda, ook jij was zeer geïnteresseerd in mijn 
cortisol onderzoek, en vol goede moed begonnen we samen aan dit onderzoek, 
een zeer leerzame tijd. Dankzij jouw vele goede ideeën over onderzoek bij 
vrouwen met een (benigne) borstafwijking, zijn we toch een andere richting op 
gegaan en is dit proefschrift tot stand gekomen met veel plezier! Veel dank voor je 
support tijdens de analyse van de data, jouw SPSS kennis was cruciaal en 
onuitputtelijk! Dank voor je geduld en het snelle beantwoorden van de zeer vele (!) 
mails die ik je heb gestuurd. Het was altijd zeer leerzaam om een artikel terug te 
krijgen met veel verbeteringen, waardoor er dan uiteindelijk geschreven stond wat 
ik wilde zeggen. Daarnaast hebben we ook veel plezier gehad in Barcelona en 
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Dr. A.F.W. van der Steeg, beste Lideke, het is een bijzonder grote eer dat ik jouw 
eerste promovenda mag zijn! Mede dankzij jouw database hebben we dit 
proefschrift kunnen schrijven. Onvoorstelbaar hoe jij alles combineert, het grote 
gezin, Kinderchirurg zijn en daarnaast meerdere onderzoekers die je met veel 
bevlogenheid begeleidt, ik heb enorm veel respect voor je! Daarbij heb je 
een ontzettend hoog tempo van terug mailen van een artikel met jouw 
opmerkingen (+ opm L) waardoor dit proefschrift zo voorspoedig en met veel 
plezier tot stand is gekomen. Jouw ideeën over wetenschappelijk onderzoek zijn 
onuitputtelijk en zeer inspirerend en hopelijk zullen we in de toekomst nog een 
aantal artikelen samen kunnen schrijven. Mede dankzij het feit dat ik jou tijdelijk 
heb vervangen in de VU, ben ik nu in opleiding tot Kinderchirurg, mijn dank 
daarvoor is nog steeds zeer groot!   
 
De overige leden van de promotiecommissie, professor dr. van Heck, dr. Schreurs, 
dr. den Oudsten, dr. Ernst en dr. Bonneux, wil ik graag bedanken voor het 
beoordelen van dit proefschrift.  
Beste Miranda, onze eerste ontmoeting was meer dan spectaculair te noemen, ik 
kijk uit naar onze volgende ontmoeting!  
Beste Hermien, zeer speciale dank gaat uit naar jou, aangezien jij me onder je 
hoede hebt genomen om wetenschappelijk onderzoek te doen tijdens de opleiding 
tot chirurg. Jij hebt me geïntroduceerd bij Anne, met dit proefschrift als resultaat, 
mijn dank hiervoor is dan ook oneindig groot! Hiermee bevestig ik jouw “succes is 
een keuze”.  
  
Lotje van Esch, mijn paranimf, heel veel dank voor de zeer prettige en gezellige 
samenwerking en de hulp bij weer een syntax error met SPSS. Mede dankzij jouw 
database hebben we deze interessante artikelen kunnen schrijven, veel dank 
daarvoor. Even op en neer naar Tilburg voor het onderzoek was altijd gezellig 
omdat we dan eerst even bij het DE café gingen bijkletsen. Zeer bijzonder om 
samen in de laatste fase van ons beider proefschrift te zijn, ten tijde daarvan waren 
we samen op congres in Wenen, wat wederom zeer gezellig was. Ik kijk uit naar 
14 december want dan mag ik met veel genoegen jouw paranimf zijn. 
 
Manon Schriek, jouw enorme inspanningen om de vrouwen te vragen of ze mee 
wilden werken aan dit onderzoek heeft mede geleid tot de database van Lideke en 
Lotje tezamen, waarop dit proefschrift gebaseerd is. Mijn idee om naast de 
vragenlijsten ook cortisol in speeksel te gaan bepalen heeft jou nog meer werk 
opgeleverd. Ondanks dat het voor vrouwen een extra belasting was, is het je toch 
gelukt om vrouwen te overtuigen mee te doen aan het cortisol onderzoek. Heel 
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veel dank voor jouw fantastische inzet, je bent echt onmisbaar voor dit onderzoek! 
 
Marlies Mertens, veel dank voor de samenwerking voor het onderzoek waarin ook 
vrouwen met galsteenziekte werden geïncludeerd. Dankzij het beschikbaar stellen 
van jouw database hebben we twee zeer interessante artikelen kunnen schrijven.   
 
Dr. Ernst, dr. Schreurs, dr. Go, dr. van Berlo, dr. Nieuwenhuijzen, dr. van der Ent 
veel dank voor jullie hulp bij het includeren van vrouwen voor deze studie in jullie 
ziekenhuis, dankzij jullie inzet hebben we nu de beschikking over een zeer grote 
database met dit proefschrift als resultaat.  
 
Mammacare verpleegkundigen en nurse practitioners (St. Elisabeth ziekenhuis in 
Tilburg, Maasland ziekenhuis in Sittard, Jeroen Bosch ziekenhuis in ’s 
Hertogenbosch, Catharina ziekenhuis in Eindhoven, VieCuri ziekenhuis in Venlo 
en Medisch Centrum Alkmaar) bijzonder veel dank voor jullie medewerking bij het 
includeren van vrouwen voor deze studie.  
 
Baliemedewerkers van de radiologie afdeling en de informatiebalie in het Medisch 
Centrum Alkmaar ontzettend veel dank voor jullie hulp bij het includeren voor onze 
(cortisol) studie en het toesturen van de vragenlijsten en cortisol watjes.  
 
De medewerkers van het laboratorium in het St. Elisabeth ziekenhuis, Karin en 
Ralf, veel dank voor jullie enthousiasme en medewerking aan het cortisol 
onderzoek. 
  
Chirurgen en assistenten van het MCA, een fantastische plek om chirurg te 
worden, heel veel dank voor de bijzonder goede en gezellige tijd!  
Chirurgen en assistenten van het VUmc, veel dank voor de zeer leerzame en 
leuke opleidingstijd tot chirurg.  
Chirurgen en assistenten in het RKZ in Beverwijk, bijzonder veel dank voor de zeer 
aangename en goede tijd, de perfecte plek om als jonge klare te beginnen.  
 
Kinderchirurgen in het VUmc en het AMC, ontzettend veel dank voor de 
zeer inspirerende en fijne tijd als fellow bij jullie. Beste Hugo, Christien, Sjoerd, 
Jeanine en Lisanne heel veel dank voor de goede en gezellige tijd in het VU 
Medisch Centrum, ik heb me heel erg thuis gevoeld bij jullie! 
  
Chirurgen en assistenten van het UMCG, dank voor de prettige samenwerking, 
dankzij de bijzonder goede werksfeer is het een waar genoegen om in het UMCG 
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eerste promovenda mag zijn! Mede dankzij jouw database hebben we dit 
proefschrift kunnen schrijven. Onvoorstelbaar hoe jij alles combineert, het grote 
gezin, Kinderchirurg zijn en daarnaast meerdere onderzoekers die je met veel 
bevlogenheid begeleidt, ik heb enorm veel respect voor je! Daarbij heb je 
een ontzettend hoog tempo van terug mailen van een artikel met jouw 
opmerkingen (+ opm L) waardoor dit proefschrift zo voorspoedig en met veel 
plezier tot stand is gekomen. Jouw ideeën over wetenschappelijk onderzoek zijn 
onuitputtelijk en zeer inspirerend en hopelijk zullen we in de toekomst nog een 
aantal artikelen samen kunnen schrijven. Mede dankzij het feit dat ik jou tijdelijk 
heb vervangen in de VU, ben ik nu in opleiding tot Kinderchirurg, mijn dank 
daarvoor is nog steeds zeer groot!   
 
De overige leden van de promotiecommissie, professor dr. van Heck, dr. Schreurs, 
dr. den Oudsten, dr. Ernst en dr. Bonneux, wil ik graag bedanken voor het 
beoordelen van dit proefschrift.  
Beste Miranda, onze eerste ontmoeting was meer dan spectaculair te noemen, ik 
kijk uit naar onze volgende ontmoeting!  
Beste Hermien, zeer speciale dank gaat uit naar jou, aangezien jij me onder je 
hoede hebt genomen om wetenschappelijk onderzoek te doen tijdens de opleiding 
tot chirurg. Jij hebt me geïntroduceerd bij Anne, met dit proefschrift als resultaat, 
mijn dank hiervoor is dan ook oneindig groot! Hiermee bevestig ik jouw “succes is 
een keuze”.  
  
Lotje van Esch, mijn paranimf, heel veel dank voor de zeer prettige en gezellige 
samenwerking en de hulp bij weer een syntax error met SPSS. Mede dankzij jouw 
database hebben we deze interessante artikelen kunnen schrijven, veel dank 
daarvoor. Even op en neer naar Tilburg voor het onderzoek was altijd gezellig 
omdat we dan eerst even bij het DE café gingen bijkletsen. Zeer bijzonder om 
samen in de laatste fase van ons beider proefschrift te zijn, ten tijde daarvan waren 
we samen op congres in Wenen, wat wederom zeer gezellig was. Ik kijk uit naar 
14 december want dan mag ik met veel genoegen jouw paranimf zijn. 
 
Manon Schriek, jouw enorme inspanningen om de vrouwen te vragen of ze mee 
wilden werken aan dit onderzoek heeft mede geleid tot de database van Lideke en 
Lotje tezamen, waarop dit proefschrift gebaseerd is. Mijn idee om naast de 
vragenlijsten ook cortisol in speeksel te gaan bepalen heeft jou nog meer werk 
opgeleverd. Ondanks dat het voor vrouwen een extra belasting was, is het je toch 
gelukt om vrouwen te overtuigen mee te doen aan het cortisol onderzoek. Heel 
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veel dank voor jouw fantastische inzet, je bent echt onmisbaar voor dit onderzoek! 
 
Marlies Mertens, veel dank voor de samenwerking voor het onderzoek waarin ook 
vrouwen met galsteenziekte werden geïncludeerd. Dankzij het beschikbaar stellen 
van jouw database hebben we twee zeer interessante artikelen kunnen schrijven.   
 
Dr. Ernst, dr. Schreurs, dr. Go, dr. van Berlo, dr. Nieuwenhuijzen, dr. van der Ent 
veel dank voor jullie hulp bij het includeren van vrouwen voor deze studie in jullie 
ziekenhuis, dankzij jullie inzet hebben we nu de beschikking over een zeer grote 
database met dit proefschrift als resultaat.  
 
Mammacare verpleegkundigen en nurse practitioners (St. Elisabeth ziekenhuis in 
Tilburg, Maasland ziekenhuis in Sittard, Jeroen Bosch ziekenhuis in ’s 
Hertogenbosch, Catharina ziekenhuis in Eindhoven, VieCuri ziekenhuis in Venlo 
en Medisch Centrum Alkmaar) bijzonder veel dank voor jullie medewerking bij het 
includeren van vrouwen voor deze studie.  
 
Baliemedewerkers van de radiologie afdeling en de informatiebalie in het Medisch 
Centrum Alkmaar ontzettend veel dank voor jullie hulp bij het includeren voor onze 
(cortisol) studie en het toesturen van de vragenlijsten en cortisol watjes.  
 
De medewerkers van het laboratorium in het St. Elisabeth ziekenhuis, Karin en 
Ralf, veel dank voor jullie enthousiasme en medewerking aan het cortisol 
onderzoek. 
  
Chirurgen en assistenten van het MCA, een fantastische plek om chirurg te 
worden, heel veel dank voor de bijzonder goede en gezellige tijd!  
Chirurgen en assistenten van het VUmc, veel dank voor de zeer leerzame en 
leuke opleidingstijd tot chirurg.  
Chirurgen en assistenten in het RKZ in Beverwijk, bijzonder veel dank voor de zeer 
aangename en goede tijd, de perfecte plek om als jonge klare te beginnen.  
 
Kinderchirurgen in het VUmc en het AMC, ontzettend veel dank voor de 
zeer inspirerende en fijne tijd als fellow bij jullie. Beste Hugo, Christien, Sjoerd, 
Jeanine en Lisanne heel veel dank voor de goede en gezellige tijd in het VU 
Medisch Centrum, ik heb me heel erg thuis gevoeld bij jullie! 
  
Chirurgen en assistenten van het UMCG, dank voor de prettige samenwerking, 
dankzij de bijzonder goede werksfeer is het een waar genoegen om in het UMCG 
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te werken.  
 
Kinderchirurgen van het UMCG, beste Robertine, Paul, Jan en Anton, veel dank 
dat jullie mij de kans hebben gegeven om bij jullie Kinderchirurg te worden. Dank 
voor het geduld en begrip dat ik de eerste periode zoveel bezig was met het 
afronden van dit proefschrift, maar nu is het echt eindelijk klaar!  
 
Medewerkers van het chirurgisch onderzoeks laboratorium in het UMCG, veel 
dank voor jullie geduld, steun en uitleg tijdens mijn eerste maanden op het lab. 
Dankzij jullie ben ik inmiddels best bekwaam geworden in de IHC en de PCR!  
 
Kamergenoten in het UMCG, beste Ewen, Sander, Patrick en Maarten, dank voor 
jullie geduld dat jullie al mijn verhalen over de laatste fase van het proefschrift en 
mijn avonturen op het lab vaak hebben moeten aanhoren. Veel dank voor de 
gezelligheid! 
  
Collega's van het OLVG, lieve Djamila, Johanna en Daphne, jullie waren (en zijn 
nog steeds) mijn grote voorbeeld. Jullie hebben mij laten zien dat je als goed 
chirurg vooral ook een hele goede dokter moet zijn! Het was een bijzonder 
leerzame maar vooral erg gezellige tijd, onder andere met z'n vieren een kamer 
gedeeld tijdens het skiweekend, een onvergetelijke tijd!  
Lieve Daphne, bijzonder veel dank voor de kans om mijn allereerste 
appendectomie te mogen verrichten, voor mij een zeer memorabele dag! 
 
Mijn anatomie maatje, lieve Mirjam, tijdens het geven van anatomie onderwijs zijn 
we vriendinnen geworden. Heel bizar dat jij eerst in Groningen hebt gewerkt. Het 
zou toch heel bijzonder zijn als we uiteindelijk in hetzelfde ziekenhuis terecht 
komen, jij als kinderarts en ik als kinderchirurg, lijkt mij een bijzondere goede 
combinatie!  
 
Mijn maatje in het VUmc, lieve Maartje, wat een waanzinnig leuke tijd hebben we 
gehad, samen in de nachtdienst, klompje schieten, samen in de organisatie van 
het zeilweekend en de chirurgencup! Jouw relativeringsvermogen en vrolijkheid is 
een groot goed! 
 
Mijn maatje in het MCA en het VUmc, lieve Hillian, heel veel dank voor de intense 
en gezellige tijd. Samen in de feest commissie was echt een top combinatie: zeilen 
met Lopes, rondje Bergen etc. Onvergetelijke momenten! Hopelijk blijven we voor 
altijd roommates bij de chirurgendagen! 
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Mijn fantastische vriendinnetjes, Barbera, Bouke, Iris, Jette en Natascha.  
Lieve Barbera, ik ben er trots op al zo ontzettend lang jouw vriendin te zijn, je bent 
een echte steun geweest in al die jaren vanaf de middelbare school tot nu toe. 
Vele avonden samen op stap, bijkletsen met een kop thee en samen sporten, het 
is altijd gezellig! Jouw relativeringsvermogen is onuitputtelijk gebleken in al die 
(turbulente) jaren!  
 
Lieve Bouke, ik ben zo blij dat je al zo lang mijn vriendinnetje bent. Vele avonden 
samen uit geweest onder andere in Flaine, echt een fantastische tijd. Samen 
tennissen is echt een groot genot, vooral daarna thee leuten of colaatjes light 
drinken en heel veel bijpraten is tijdens alle hectiek van de afgelopen jaren zeer 
aangenaam geweest. Heel bijzonder om samen in Rome én Groningen op stap te 
zijn geweest, wat is ons volgende uitje?  
 
Lieve Iris, vanaf het eerste jaar geneeskunde kennen we elkaar en hebben we 
heel wat uren samen doorgebracht in de collegezalen, op Plein J, op de 
Nieuwmarkt of bij Asklepios. Samen met jou een avondje bijpraten vliegt voorbij en 
dan hebben we nog niet alles besproken! Dank voor al die gezelligheid!  
 
Lieve Jette, samen medische biologie studeren op de Anna's Hoeve (onze haai 
bleek geen Fred maar Frida te zijn), een zeer bijzondere tijd waar de basis van 
onze fijne vriendschap is gelegd. Niets zo prettig als we elkaar na een lange tijd 
weer spreken alsof ons laatste gesprek gisteren is geweest!  
 
Lieve Natascha, samen zo ontzettend veel meegemaakt: onder andere samen 
turnen, het vele uitloten, uitgaan in het stadje of de stad en vele uren kletsen met 
een kop thee. Voor mij echt een zeer waardevolle vriendschap, hopelijk nu weer 
tijd om samen nieuwe herinneringen te maken! 
  
Lieve schoonouders en schoonfamilie, heel veel dank voor jullie support en begrip 
in al die jaren dat ik toch weer niet mee kwam eten omdat ik moest werken aan het 
onderzoek of weer eens dienst had. Hopelijk nu weer vaker tijd om samen Soto te 
eten, en dan niet "sudah makan pulan"!  
 
Lieve Noah, veel dank voor de leuke en gezellige momenten samen waardoor ik 
alles nog beter kan relativeren, het is elke keer een feestje als je bij ons komt 
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te werken.  
 
Kinderchirurgen van het UMCG, beste Robertine, Paul, Jan en Anton, veel dank 
dat jullie mij de kans hebben gegeven om bij jullie Kinderchirurg te worden. Dank 
voor het geduld en begrip dat ik de eerste periode zoveel bezig was met het 
afronden van dit proefschrift, maar nu is het echt eindelijk klaar!  
 
Medewerkers van het chirurgisch onderzoeks laboratorium in het UMCG, veel 
dank voor jullie geduld, steun en uitleg tijdens mijn eerste maanden op het lab. 
Dankzij jullie ben ik inmiddels best bekwaam geworden in de IHC en de PCR!  
 
Kamergenoten in het UMCG, beste Ewen, Sander, Patrick en Maarten, dank voor 
jullie geduld dat jullie al mijn verhalen over de laatste fase van het proefschrift en 
mijn avonturen op het lab vaak hebben moeten aanhoren. Veel dank voor de 
gezelligheid! 
  
Collega's van het OLVG, lieve Djamila, Johanna en Daphne, jullie waren (en zijn 
nog steeds) mijn grote voorbeeld. Jullie hebben mij laten zien dat je als goed 
chirurg vooral ook een hele goede dokter moet zijn! Het was een bijzonder 
leerzame maar vooral erg gezellige tijd, onder andere met z'n vieren een kamer 
gedeeld tijdens het skiweekend, een onvergetelijke tijd!  
Lieve Daphne, bijzonder veel dank voor de kans om mijn allereerste 
appendectomie te mogen verrichten, voor mij een zeer memorabele dag! 
 
Mijn anatomie maatje, lieve Mirjam, tijdens het geven van anatomie onderwijs zijn 
we vriendinnen geworden. Heel bizar dat jij eerst in Groningen hebt gewerkt. Het 
zou toch heel bijzonder zijn als we uiteindelijk in hetzelfde ziekenhuis terecht 
komen, jij als kinderarts en ik als kinderchirurg, lijkt mij een bijzondere goede 
combinatie!  
 
Mijn maatje in het VUmc, lieve Maartje, wat een waanzinnig leuke tijd hebben we 
gehad, samen in de nachtdienst, klompje schieten, samen in de organisatie van 
het zeilweekend en de chirurgencup! Jouw relativeringsvermogen en vrolijkheid is 
een groot goed! 
 
Mijn maatje in het MCA en het VUmc, lieve Hillian, heel veel dank voor de intense 
en gezellige tijd. Samen in de feest commissie was echt een top combinatie: zeilen 
met Lopes, rondje Bergen etc. Onvergetelijke momenten! Hopelijk blijven we voor 
altijd roommates bij de chirurgendagen! 
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Mijn fantastische vriendinnetjes, Barbera, Bouke, Iris, Jette en Natascha.  
Lieve Barbera, ik ben er trots op al zo ontzettend lang jouw vriendin te zijn, je bent 
een echte steun geweest in al die jaren vanaf de middelbare school tot nu toe. 
Vele avonden samen op stap, bijkletsen met een kop thee en samen sporten, het 
is altijd gezellig! Jouw relativeringsvermogen is onuitputtelijk gebleken in al die 
(turbulente) jaren!  
 
Lieve Bouke, ik ben zo blij dat je al zo lang mijn vriendinnetje bent. Vele avonden 
samen uit geweest onder andere in Flaine, echt een fantastische tijd. Samen 
tennissen is echt een groot genot, vooral daarna thee leuten of colaatjes light 
drinken en heel veel bijpraten is tijdens alle hectiek van de afgelopen jaren zeer 
aangenaam geweest. Heel bijzonder om samen in Rome én Groningen op stap te 
zijn geweest, wat is ons volgende uitje?  
 
Lieve Iris, vanaf het eerste jaar geneeskunde kennen we elkaar en hebben we 
heel wat uren samen doorgebracht in de collegezalen, op Plein J, op de 
Nieuwmarkt of bij Asklepios. Samen met jou een avondje bijpraten vliegt voorbij en 
dan hebben we nog niet alles besproken! Dank voor al die gezelligheid!  
 
Lieve Jette, samen medische biologie studeren op de Anna's Hoeve (onze haai 
bleek geen Fred maar Frida te zijn), een zeer bijzondere tijd waar de basis van 
onze fijne vriendschap is gelegd. Niets zo prettig als we elkaar na een lange tijd 
weer spreken alsof ons laatste gesprek gisteren is geweest!  
 
Lieve Natascha, samen zo ontzettend veel meegemaakt: onder andere samen 
turnen, het vele uitloten, uitgaan in het stadje of de stad en vele uren kletsen met 
een kop thee. Voor mij echt een zeer waardevolle vriendschap, hopelijk nu weer 
tijd om samen nieuwe herinneringen te maken! 
  
Lieve schoonouders en schoonfamilie, heel veel dank voor jullie support en begrip 
in al die jaren dat ik toch weer niet mee kwam eten omdat ik moest werken aan het 
onderzoek of weer eens dienst had. Hopelijk nu weer vaker tijd om samen Soto te 
eten, en dan niet "sudah makan pulan"!  
 
Lieve Noah, veel dank voor de leuke en gezellige momenten samen waardoor ik 
alles nog beter kan relativeren, het is elke keer een feestje als je bij ons komt 
logeren, en wie wil er nou niet met jou een kussengevecht doen?  
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Lieve oma, bijzonder veel dank voor uw intense liefde voor ons, uw enorme 
levenswijsheid, de fantastische (jeugd) herinneringen, de vele sinaasappelen en 
prachtige breisels. Ik ben er echt heel trots op uw kleindochter te zijn!  
 
Lieve Desiree, lieve zus, heel veel dank voor je fantastische hulp bij de laatste 
correcties van dit proefschrift. Bijzonder veel dank voor al je support, goede raad, 
gezelligheid en onvoorwaardelijke zusterliefde. Je bent heel belangrijk voor mij als 
grote zus, zo ontzettend veel samen meegemaakt, vriendinnen voor het leven! 
Eindelijk weer eens tijd om vaker samen een concert te bezoeken of op pad te 
gaan in Amsterdam of London!  
 
Lieve papa en mama, jullie zijn onvoorstelbaar lieve ouders. Jullie 
onvoorwaardelijke liefde en intense "life-time commitment" aan ons is zo 
ontzettend bijzonder en hartverwarmend. Vele koppen thee en wijze woorden 
hebben we gedeeld aan de eettafel. Dankzij jullie steun op elk denkbaar moment 
en doordat altijd alles mogelijk was, heb ik echt alles kunnen doen wat ik wilde! 
Mijn dank is groter dan oneindig groot! Ik ga niet zeggen dat de turbulente tijden nu 
eindelijk voorbij zijn, “never a dull moment” zal nog vaak gezegd worden! 
 
Lieve Micha, mijn liefje en maatje sinds 1995, daarom ook mijn paranimf. Je 
hebt nooit geklaagd over dat ik weer aan mijn onderzoek wilde werken of toch 
weer even wat langer bleef werken om een operatie te kunnen doen. Het is een 
bizarre tijd geweest de afgelopen maanden: verhuisd naar Groningen, latten na 15 
jaar samenwonen, in opleiding tot Kinderchirurg en het proefschrift afronden. Veel 
dank voor je onuitputtelijke liefde, support en relativering tijdens het waarmaken 
van al mijn ambities; geneeskunde studeren, chirurg worden, promoveren, 
kinderchirurg worden, what's next? Hopelijk gaan we samen nog heel vaak "dolce 
far niente" meemaken! 
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